Subject Index For Volume 47

Subject Index For Volume 47 A

ABO-incompatible transplant, hemolytic anemia (abst) . . . 362 680 Acetazolamide, NaHCO1 cotransport, PT (abst) Acid-base balance. See pH Acidosis 1205 adaptation trade-offs, Nephrology Forum 624 chronic renal, urinaly parameters, pH 354 metabolic, anion gap, HD (abst) 355 metabolic, CRF (abst) 355 metabolic, hyperkalemia therapy (abst) osteoblastic intracellular pH and Ca 1790 1816 renal osteodystrophy, Nephrology Forum 1220 Actin, aminopeptidase A, BBM (abst) Acute bacterial nephritis 344 characteristics (abst) 344 clinical aspects (abst) 362 Acute pyelonephritis graft kidney, RF (abst) Acute renal failure (ARF) continuous hemofiltration (abst) 989 974 erythropoietin in (abst) 996 fibrinolysis, prostaglandins, ET-1 (abst) insulin-like growth factor-i 1658 985 ischemic, differing HD membranes (abst) 343 post-extracorporeal circulation (abst) 968 post-transplant (abst) 1004 pre-eclampsia (abst) 1569 recovery with zaprinast 217 Acute respiratory alkalosis, plasma protein response 628 Acute tubular necrosis, cytoresistance, hypoxic injury Adenosine 1000 extracellular ATP, mitogenic effect, MC (abst) 681 extracellular NaC1, TAL (abst) 686 hypersensitivity, glomeruli, low-Na rats (abst) infusion rate, renal effect (abst) 699 1576 Na transport, A1 receptor, [Ca2]1 signaling, human CD cells 1310 996 transjunctional, cs2-autoreceptors (abst) 322 Adenovirus-mediated gene transfer 38 Adenylate cyclase, desensitization, PKC, PTH ADH, Na/H exchange, Ang II, diadenosines, CCD (abst).. 999 Adhesion molecules 370 biopsy, post-transplant (abst) 350 hemorrhagic fever with renal syndrome (abst) proteins interact with HD membranes 1115 1624 Adipocytes, elevated cytosolic Ca, CRF Adriamycin 673 glomerulopathy, fibronectin, silibinin (abst) 1223 nephrosis, ACEi, Ang II, bradykinin (abst) Advanced glycosylation end products (AGEs) 49:S-55 ECM gene expression, DM, GS 1768 formation, PD fluid 1221 Afferent arteriolar response, Tolrestat (abst) Age 962 antihypertensive agents, compared (abst) 968 infradian bioperiodicity, urinary enzymes (abst) 986 intrarenal resistance index, EH (abst) 996 pediatric donor kidney matching (abst) 997 rejection episodes (abst)

Albumin 421 apoprotein B degradation based PD solutions (abst) 358 1031 binding, glomerular capillary wall Albuminuria. See also Microalbuminuria ANP, natriuresis, glomerular permeability, NS (abst) ... 993 1008 CsA-associated arteriopathy, proteinuria (abst) 701 heparan sulfate, GBM, lupus nephritis (abst) 992 Na intake, EH (abst) 1078 single nephron 1217 single nephron (abst) 217 Alkalosis, acute respiratory, K response 972 Alloantibodies, "early graft dysfunction" (abst) 706 Allogeneic transplantation, tolerance (abst) Allografts 362 acute pyelonephritis, RF, post-transplant (abst) 703 biopsy, interstitial edema, infiltrate (abst) 703 biopsy during rejection (abst) 360 GFR pre/post-transplant (abst) 965 hyperparathyroidism (abst) metabolic risk factors (abst) 979 nonimmunologic late graft loss, Nephrology Forum ... 1470 981 optimizing survival (abst) 361 recipient IgA nephropathy (abst) 707 sex/age and survival (abst) 1136 survival, hypertension and race 368 tolerance induction, coichicine (abst) 663 a-ketoglutarate, PAH secretion (abst) 996 a2-autoreceptors, adenosine (abst) Alport syndrome 371 asymptomatic women carriers, living donors (abst) autosomal recessive 1142 basement membrane molecular genetics 49:S-29 758 bull terrier hereditary nephritis COL4A3 gene mutation 1199 327 prenatal diagnosis 354 Aluminum hydroxide, serum Al, ESRD (abst) Aluminum toxicity microcytosis

164

983 RI and transplantation (abst) 966 AMBIO dialyzer biocompatibility (abst) Amino acids based dialysate, malnourished CAPD patients 1148 free, cortex and outer medulla, ischemia (abst) 991 oxidative phosphorylation diseases 1101 679 PT gp330, endocytosis, aprotinin (abst) rBAT and heavy metal intoxication 1677 592 21-aminosteroids, renal injury 1101 Aminoaciduria, oxidative phosphorylation diseases 685 Aminoguanidine, IGF-1, NOS (abst) Aminopeptidase A 1220 actin, brush border membranes (abst) 1221 monoclonal anti-APA antibodies, PT (abst) Aminopeptidase N, EGF, 5'-NU, glomerular MC (abst)... 699 Amyloidosis, plasma exchange, cytotoxic drugs (abst)... . 1485 Analgesic nephropathy, urothelial carcinoma, post984 transplant (abst)

1877

1878

Anaphylaxis, parathyroidectomy, heparin, thrombocytopenia (abst) Anemia autoimmune hemolytic, ABO-incompatible transplant (abst) renin-angiotensin axis, CRF (abst) Angiogenesis cytokines, proteolysis (abst) pp60c-src, activated PDGF (abst) stimulated by rHuEPO Angiotensin (1-7), renal response (abst)

Subject Index: Vol. 47

1003

362

Anticardiolipin antibodies, vascular access clotting, SLE (abst) Antidiuresis, stress induced, Ang lIr blockade (abst) Antiendothelial antibodies, Wegener's granulomatosis (abst)

1484 668 973

354 Antihypertensive agents 659 660 740

975 1176 Angiotensin-converting enzyme (ACE) gene and DN....

1223

antiproteinuric effects (abst) elderly, compared, children (abst) elderly, microalbuminuria (abst) long-term therapy, DN, GFR microalbuminuria (abst) renal effects, early CRF (abst) Antiphospholipid antibodies (APA) HD patients (abst) SLE (abst)

962 962 1726 962 353

Angiotensin-converting enzyme (ACE) inhibition 1481 1394 Ang II blockade, 2-K, 1-C hypertension 369 1223 antiproteinuria, adriamycin nephrosis (abst) 1224 Antiproteinuric effect antiproteinuria, renal/systemic hemodynamics (abst). 1223 ACEi, adriamycin nephrosis (abst) 1319 endothelin, prevent RF/death 1224 ACEi, renal/systemic hemodynamics (abst) 676 glomerular filtration, mesangial volume (abst) 1223 antihypertensive agents (abst) 274 intrarenal, Ang I and II 1638 907 Antisense angiotensinogen, transgenic mice plasma lipids, DN 274 Antisense oligonucleotides, genes, organ development Angiotensin I (Ang I), intrarenal ACEi, renal response 693 (abst) Angiotensin II (Ang II) 687 Aortic valve regurgitation, hypertensive nephrosclerosis ET, mitogenic response, endothelial cells (abst) 981 (abst) 701 heparan sulfate proteoglycans, MC (abst) Apolipoproteins 131 modulates PDGF 706 glomerular deposits, analbuminemia (abst) Na/H exchange, ADH, diadenosines, CCD (abst) 442 renal deposits, UNX analbuminemia 696 PKC, proximal tubule (abst) 421 1220 Apoprotein B degradation, albumin renal nerve, RPP reduction (abst) . . . 965 Apoprotein(a) isoforms, atherosclerosis, CAPD (abst) . Angiotensin II (Ang II) receptors 1285 Apoptosis antagonist, obstructive nephropathy 411 clusterin expression, renal regeneration 668 blockade, antidiuresis, anti-natriuresis (abst) 657 glomerulonephritis (abst) ontogeny, 140, 1095 694 HgCl2 T-cell hybridoma, cytokines (abst) 1638 Angiotensinogen, antisense, transgenic mice 1806 intrarenal, hypoxia 1630 Anionic horseradish peroxidase, charge selectivity 671 neutrophils, CD36 eDNA transfection (abst) Anionic transport, peritoneal mesothelium, SITS and 114 proliferative GN 683 DIDS (abst) 688 proliferative GN (abst) 964 Antegrade pyelography, acutely dilated pyelon (abst) 696 AQP-CD water channel, vasopressin (abst) Anti-glomerular basement membrane (GBM) antibodies 350 Arteriopathy GN, glomerular crescent formation (abst) 1008 CsA-associated, proteinuria, albuminuria (abst) 350 Goodpasture's disease (abst) 998 CsA-associated, renal biopsy (abst) Anti-HLA-I antibodies, anti-idiotypic antibodies, Arteriovenous fistulae 1483 platelets (abst) 1484 clotting, coagulation abnormalities (abst) 982 Anti-infective therapy and RI (abst) 1484 PTFE grafts, seroma formation (abst) Anti-myeloperoxidase (MPO) antibodies 664 Aspirin, renal ammoniagenesis (abst) 193 ANCA-associated GN 1216 AT-ir antagonist, essential hypertension (abst) 1121 ischemia/reperfusion injury, GN 965 CAPD patients (abst) 368 Atherosclerosis, microscopic polyarteritis, transplantation (abst) ATP 454 nephrotoxic serum nephritis 700 extracellular, membrane voltage, MC (abst) Anti-natriuresis, stress induced, Ang lIr blockade (abst). . . 668 1000 extracellular, mitogenic effect, MC (abst) Anti-neutrophil cytoplasmic autoantibodies (ANCA) 705 extracellular, Na transport, PKC (abst) 454 anti-MPO antibodies and GN 679 mitochondrial synthase, developing kidney (abst) 193 GN, anti-PR3 renal disease 669 phospholipase C, c-fos, P2u-receptors, MC (abst) 1528 Atrial natriuretic factor (ANF), compared, urodilatin. . . 1558 proteinase 3, Wegener's granulomatosis vasculitis, ANCA isotype, pulmonary hemorrhage Atrial natriuretic peptide (ANP) 365 692 (abst) growth suppression, MC, TGF-/3 (abst) 682 Anti-Thy-i nephritis, fibronectin, glomerular changes ICV immunoneutralization, renal function (abst) 698 (abst) natriuresis, albuminuria, glomerular permeability, NS 993 Anti-thymocyte-antibody complement, renal (abst) 686 1002 hemodynamics (abst) plasma concentration, HD (abst) 686 renal hemodynamics, acute volemic stress (abst) Anti-thymocyte globulin (ATG) 706 sino-carotid denervation, endocrine function (abst) 683 allogeneic transplant, tolerance (abst) 708 sino-carotid denervation, renal function (abst) 668 Wegener's granulomatosis (abst) 994 Autoimmune hemolytic anemia, ABO-incompatible Antibiotic prophylaxis, staphylococcus, CRIs (abst) 362 Antibodies, glomerular deposits, isoelectric point (abst). . 1006 transplant (abst) .

Subject Index: VoL 47

Autosomal dominant polycystic kidney disease (ADPKD) 995 autoregulatory reserve (abst) 354 clinical study (abst) 716 epithelial differentiation 995 ET-1 role (abst) 727 fibroblast growth, ECM metabolism 728, 729 genetic study 985 genotype and phenotype (abst) molecular basis 715 552 new mouse PKD mutant 1218 normotensive, i.v. dopa (abst) 967 pressure-dependent renin secretion (abst) 1002 prognosis, primary hypertension (abst) solute and fluid secretion 723 368 transplantation (abst) 861 tubulogenesis, cyst-derived cells Autosomal recessive polycystic kidney disease (ARPKD) EGFr expression, CPK mouse kidney 490 MMP expression and TIMP (abst) 659 molecular basis 715 new mouse PKD mutant 552 Azathioprine 975 compared, CsA monotherapy (abst) 1221 glomerular barrier function, CsA (abst)

J32-adrenoceptor-agonists

hyperkalemia therapy (abst) hypokalemia, lactatemia post-therapy (abst) J32-microglobulin

adsorption, HD membranes (abst) bone disease and bone loss, IL-113, prostaglandins deposits, math model for

(32-M as mediator

587 1

969 969

C

49:S-19 49:S-59

356 1

587 1453

urinary excretion, membranous nephropathy (abst).... 1218

f33 integrin, crescentic GN (abst) Bicarbonate excretion, regulation by kallikrein (abst)

/32-M, IL-113, prostaglandins

370 352 352

1811 Babylonia, ancient, renal/urinary tract disease 986 Bacteremia, E. col4 interstitial nephritis (abst) Bacterial infection 999 HCV, HBsAg, CD14, HD (abst) 974 LPS-induced GN, INF-y (abst) LPS-induced IL-6 gene, cAMP (abst) 694 1005 spectrum UTI, post-transplant (abst) 207 superantigen, MRSA infection, nephritis Baculovirus-infected cells, renal Na/P1-cotransport (abst) . . 662 663 Barium effect, Na reabsorption (abst) 364 Bartter syndrome with hypocalciuria (abst) Basement membranes AGEs induce ECM gene overexpression, DM, GS.. 49:S-55 cell-cell cross-talk, interstitial renal fibrosis 49:S-48 49:S-8 cell-extracellular interactions, signalling 49:S-15 crinopexy 49:S-12 ECM remodeling models of nephron reduction 49:S-51 49:S-29 molecular genetics, Alport syndrome renal disease progression, chemokines 49:S-44 49:S-4 structure, supramolecular organization

J3 integrin crescentic UN (abst) expression, ICAM-1, MC, GN (abst) expression, ICAM-1, MC, high glucose (abst)

1001 loss, theophyllin, UTI, DM, post-transplant (abst) 667 transport, medullary hypotonicity (abst) Biocompatibility dialysis membranes, oxygen radicals as marker (abst) . . . 995 1218 dialyzer elution technique (abst) 966 HD membranes compared (abst) 987, 993 Bioelectrical impedance analysis (BIA) (abst) Biopsy. See Renal biopsy Biphasic TNF-a in MRL-lpr mice 122 Blood pressure 977 24-hour monitoring with FK506, CsA (abst) 978 ambulatory monitoring, EH, salt intake (abst) 1223 antihypertensives, antiproteinuric effects (abst) 963 arterial/venous changes, uremia (abst) 1216 enalapril, nifedipine, renal response, ET (abst) 1017 heparin lowers 987 insulin sensitivity, CsA therapy (abst) renin mRNA, renin secretion, RA stenosis (abst) 978 964 vessel wall properties, post-transplant (abst) Body fluid composition, evaluation with BIA (abst) 993 Bone disease acidosis and renal osteoclystrophy, Nephrology Forum . 1816

IGF-1 mRNA in GH-treated uremic bone 1374 1000 low turnover osteopathy, long-term HD (abst) 1008 osseus malformations, nephronophthisis (abst) 1434 pre-dialysis/dialysis patients 1746 secondary hyperparathyroidism, uremia, DM Bone marrow 706 allogeneic transplant, tolerance (abst) 966 CsA increases plasma prorenin (abst) fibrillary deposits, immunotactoid-like glomerulopathy 998 (abst) 1008 transplant, CsA, arteriopathy (abst) Bone metabolism 347 children, NS, steroids (abst) 969 low-calcium dialysate, CAPD (abst) 983 mass reduction dynamics, HD patients (abst) Bone mineral density, Ca transport, hypercalciuria (abst). . 363 Bradykinin, antiproteinuria, adriamycin nephrosis (abst). . 1223 Brain natriuretic peptide, plasma concentration, HD 1002 (abst) Brush-border membranes 1220 actin, aminopeptidase A (abst) 971 Cl conductance, porcine (abst) 1048 fluidity, Na-coupled uptake, cisplatin 965 human urine, proteins mark PT injury (abst) 686 inositol lipid signalling system (abst) 989 renal tubular enzymes, urinary excretion (abst) 708 BT563 (anti-IL-2R MoAb) prevents rejection (abst) 758 Bull terrier hereditary nephritis 354 Bumetanide, pharmacokinetics, NS (abst)

B

TGF-f3, an overview TGF-13 mediates US

1879

370 681

c-fos expression calcium channel blocker, ischemic injury (abst) extracellular ATP, phospholipase C, P2u-receptors,

MC (abst) C-type natriuretic peptide plasma concentration, HD (abst) proinsulin, neuropeptide Y, Na/K-ATPase (abst) receptors, human MC (abst) Clq, IgG binding, mesangial cells (abst)

343 669

1002 678 682 671

1880

Clq nephropathy biopsy analysis (abst) with minimal change NS (abst)

Subject Index: Vol. 47

347 347

C3

829 biosynthesis, human mesangial cells 371 local transcription, allograft rejection (abst) 671 C4, MC synthesis, cytokines, MHC antigen (abst) C4d, capillary deposits, "early graft dysfunction" (abst) . . . 972 1604 C6 deficiency, active Heymann nephritis Ca2 activated K channel, human colonic T84 cells (abst). . . . 680 991 dependent Cl conductance (abst) 700 extracellular nucleotides, cortical TAL (abst) 972 influx, epithelial cells (abst) 669 oscillations/interactions, RAS oncogene (abst) 1790 osteoblastic intracellular, acidosis 343 oxidant-induced PT cell injury (abst)

[Ca2I adenosine, Na transport, A1 receptor adipocytes, chronic renal failure carbohydrate metabolism, PMNL, verapamil PTH-PTHrP receptor of heart, CRF Calcitriol i.v., insulin sensitivity, uremia

1576 1630 1741

1182

200

369 oral, zero calcium solutions, CAPD (abst) 991 oral bolus, predialysis CRF (abst) Calcium 364 absorption, Bartter syndrome, hypocalciuria (abst) 1266 cell regulation, renin gene expression, cAMP 363 erythrocyte transport, hypercalciuria (abst) 363 intestinal absorption, bone mineral density (abst) intracellular, ouabain-like factor, inner medullary CD 1006 cells (abst) 675 renal renin secretion (abst) Calcium channel blockers 702 cellular Ca, cell injury, anoxia, PT (abst) 343 EGF, c-fos gene expression, ischemia (abst) 702 felodipine, H 186/86, hypoxic PT (abst) 345 Na/K-ATPase, acute ischemic RF (abst) Calcium dialysate 356 Ca-free levels, HD, hypercalcemia (abst) 969 Ca-low levels, bone metabolism, CAPD (abst) 899 Calciuria, K-deprivation, salt restriction 345 Calculi, ESWL monotherapy (abst) Cancer 980 factors associated with transplantation (abst) 988 lymphoma incidence post-transplant (abst) 980 malignant lymphoma, EBV, post-transplant (abst) 1006 malignant tumors post-transplant (abst) renal cell carcinoma, peripheral T-cell subsets (abst) . . . 345 urothelial, analgesic nephropathy, post-transplant 984 (abst) 1515 Captopril, L-arginine, nitric oxide, CRF 1219 Carbamylated hemoglobin as index of uremia (abst) Carbohydrate metabolism, [Ca2]1 PMNL, verapamil. . . . 1741 703 Cardiac interstitial fluid, RAS components (abst) 684 Cardiac myocyte function, CRF (abst)

Cardiac PTH-PTHrP receptor, [Ca2} CRF

1182

Cardiovascular disease cardiac rhythms, ESRD, HD CHF, dialysis patients complications, post-transplant (abst) coronary artery calcification (abst) events post-transplant (abst) ischemic, Lp(a), CAPD (abst)

1443 884 980 967 979 357

186 patients starting ESRD therapy 987 prevention, HD (abst) 998 Carotid artery, structural changes, CRF (abst) Cathepsin S 1000 catalytic activity, PT (abst) 665 in kidney (abst) 994 Catheter-related infections, prophylaxis (abst) 688 Cationized Ig aggregates, glomeruli (abst) CD14 999 HCV, HBsAg, bacterial infections, HD (abst) 973 soluble, high serum levels, HD (abst) 670 CD16, (Fcy receptor III), glomerular MC (abst) CD36, cDNA cell transfection, neutrophils, apoptosis 671 (abst) 672 CD43, release from neutrophil membrane (abst) CD44, neutrophil proteases, induce MC shedding (abst) .. 671 CD59, urinary, complement SC5b-9, cytokines, MGN.... 1403 1048 cDDP, BBM fluidity, Na-coupled uptake 49:S-48 Cell-cell cross-talk, interstitial renal fibrosis 49:S-8 Cell-extracellular matrix interactions Cell volume 681 effects on pH, acidic cellular compartments (abst) 697 oscillates with migration of MDCK-F cells (abst) 674 regulation, cloned Cl channel from EC (abst) 980 Cerebrovascular complications, post-transplant (abst) 720 CFTR, cloning, mutations and functions cGMP 999 activating agonists, membrane voltage, CCD (abst) 666 intracellular synthesis, somatostatin, MC (abst) 657 Channels and pumps (abst) 1242, 1630 Charge selectivity Chemokines 660 glomerular, nephrotoxic nephritis (abst) 49:S-44 renal disease progression Children 962 antihypertensive therapy (abst) 705 complement, serum/dialysate, CAPD (abst) 1690 FSGS, distribution of lesions 347 NS, bone metabolism, steroids (abst) 1392 NS, mild, steroid-responsive 346 NS, sonography (abst) 346 NS, urinary f32-M, proteinuria (abst) 344 pyeloplasty, UUO (abst) 1108 reflux nephropathy, glomerular morphometry 951 treatment of CRF, Nephrology Forum 662 CHIP-FA amphibian water channel (abst) 989 Cholesterol loading, lipoprotein(a), MC (abst) Chronic renal failure (CRF) 1624 adipocytes, [Ca2}, 354 anemia, renin-angiotensin axis (abst) 1515 captopril, L-arginine, nitric oxide 684 cardiac myocyte function (abst) 998 carotid artery, structural changes (abst) 951 children, Nephrology Forum 1231 chronic viral hepatitis 998 cytokine autoantibodies (abst) 158 excess PTH, lung and right ventricle 969 exercise, serum K changes (abst) 1182 heart PTH-PTHrP receptor, [Ca2J1 role 1522 hepatocyte metabolism 357 Lp(a) and lipid profiles (abst) 355 metabolic acidosis (abst) 991 oral calcitriol bolus, predialysis (abst) 353 protein intake, anti-hypertensives (abst) 7 protein intake, urine concentration

Subject Index: Vol. 47

serum/urine neopterins (abst) .

torasemide therapy (abst) Cirrhosis, renal ET-1 receptor subtypes (abst) Cisplatin epithelial transport system (abst) modulated Na-coupled uptake, BBM fluidity

353

992 976 343 1048

Cl-

channels, EC, cell volume regulation (abst) conductance, BBM vesicles (abst) conductance, Ca-dependent, MC swelling (abst) dependent taurine reabsorption, furosemide (abst) intake, hypertension, PKD (abst) renin secretion, juxtaglomerular cells (abst) transport inhibitors in epithelia "Clearance peak" PD prescription model (abst) Clearance study Na reabsorption, Henle's loop (abst) tubular site of action, furosemide (abst) Clusterin expression, apoptosis, renal regeneration Coagulation endothelin role regulatory protein loss, thrombosis, CAPD (abst) COL4A3 gene mutation, Alport syndrome COL4A5, prenatal diagnosis of Alport syndrome Coichicine, allograft tolerance (abst) Collagen GS, progression predictors molecular properties, diseases of Collagen-I subchains, differential expression, GS (abst) synthesis regulation Collagen-IV

674 971 991

997 973 675

722 371

667 682 411 795 990 1199 327 368

49:S-39 49:S-24 698

49:S-34

1142 distribution, Alport syndrome 404 EHS, lacking Goodpasture's epitope, GN 698 regulation, s5(IV), NIH3T3 cells (abst) Collagenase-IV 92/72-kDa, SV4O oncogene, collecting tubule (abst) .... 665 5' region, 72 kD, MC enhancer (abst) 974

Collecting ducts 92/72-kDa collagenase-IV, SV4O oncogene (abst) adenosine signaling enriched rabbit cortical, ficoll gradient inner medullary, acid-base transport, Nephrology Forum inner medullary, organic osmolytes, G-proteins (abst). . . intercalated cell properties, MDCK cells

665 1310

306 333

996 679

papillary, Na transport, interstitial cell culture (abst) . . . 973 papillary pH gradient, urine, vasa recta, diuresis 681, 987 (abst) principal cells, proteoglycans, Simian virus 40 (abst). . . . 698 WCH-CD endosome distribution, vasopressin (abst). . . . 675 Complement 1604 active Heymann nephritis anti-thymocyte-antibody, renal hemodynamics (abst). ... 686 671 Clq subunit, IgG binding, MC (abst) 971 deposits, "early graft dysfunction" (abst) Factor B and C4, MC, cytokines, MHC antigen (abst) . . 671 371 local transcription, rejection (abst) 1403 SC5b-9, urinary, CD59, cytokines, MGN 705 serum/dialysate, children, CAPD (abst) terminal cascade activation, renal infarction 918 967 Computer tomography, coronary arteries (abst) 367 Conductivity kinetic model (abst) Congestive heart failure and dialysis 884 987 Connective tissue disease, membranous GN (abst)

1881

Continuous ambulatory peritoneal dialysis (CAPD). See also Dialysate acid-base balance in 269 atherosclerosis 965 993 BIA, body fluid composition (abst) 1434 bone disease, PTH response 969 Ca dialysate, low-level, bone metabolism (abst) 369 Ca dialysate, zero-level, oral calcitriol (abst) 705 complement in serum/dialysate, children (abst) 994 intraperitoneal cytokines, without peritonitis (abst) lactate-buffering, mesothelial cell function 282 966 long-term experience, 164 patients (abst) Lp(a), ischemic heart disease (abst) 357 nitrate levels (abst) 1217 359 nutritional assessment, HD (abst) nutritional assessment, urea kinetic modeling (abst) . . . . 358 997 peritoneal fibrinolysis, mesothelial cells (abst) 358 peritoneal fibrosis, peritonitis (abst) 1004 pregnancy with (abst) 978 quantification, clinical outcome (abst) rhGH effects, undernourished adults (abst) 359 standard peritoneal permeability analysis, PET (abst) . . 1217

thrombosis, coagulation regulatory protein loss (abst)... 990 Contrast media 983 iodine monitoring, RI (abst) 254 ionic/nonionic, nephrotoxicity 342 nephrotoxicity, N-acetyl-f3D-glucosaminidase (abst) nitrendipine, urinary enzyme, protein excretion (abst). . . 369 988 nonionic, pharmacokinetics, RI (abst) Coronary artery disease 967 calcifications, non-invasive measurement (abst) 368 risk assessment, elderly, pre-transpiant (abst) Cortical collecting ducts 659 cell volume dependent NA,K!ATPase pump (abst) cGMP activating agonists, membrane voltage (abst). ... 999 306 enriched rabbit, ficoll gradient microtubule content increase, cAMP (abst) 662

Na/H exchange, ADH, Ang II, diadenosines (abst) . . 999 705 Na transport, extracellular ATP, PKC (abst) Crescentic glomerulonephritis i3 integrin, ICAM-1, VCAM-1 counter-receptors 370 (abst) IL-Ira halts established 1303 Crinopexy, extracellular regulation of GF action 49:S-15 1483 Crush syndrome, ET receptor antagonism (abst) 367 Cryoglobulinemia, HCV, renal involvement (abst) CTLA4Ig 241 as novel antirejection strategy 370 short-term immunosuppression (abst) Cuprophane membranes, AMBIO dialyzers compared 966 (abst) Cyclic adenosine monophosphate (cAMP) adenosine signaling, CD cells 1310 1266 cell regulation, renin gene expression 992 dexamethasone, IL-1J3-induced NOS, MC (abst) 685 GFR elevation, glucagon, urea (abst) IL-i induces IL-8, IL-6 in human MC (abst) 687 694 LPS-induced IL-6 gene expression (abst) 662 microtubule content increase, CCD (abst) 688 protein kinase, glomeruli function (abst) as second messenger, organic anion transport (abst). . . . 977

Cyclooxygenase-Il ET-1, mesangial cells gene expression, tyrosine phosphorylation, IL-1f3

Cyclooxygenases, IL-i regulation, MC (abst)

53 1354 686

1882

Cyclosporin A ET-1, cell-cell interaction (abst) NO generation, endothelial cells (abst) NS, children, INF-y, steroids, lgE-R2 (abst) plasma prorenin in bone marrow (abst)

urinary TxB2 PGF1 post-transplant (abst)

Subject Index: Vol. 47

670 670 346 966

360

Cyclosporine

arteriopathy, proteinuria, albuminuria (abst) autoimmune hemolytic anemia, ABO-incompatible transplant (abst) blood trough level variability (abst) glycosylation (abst)

membranous nephropathy urinary ET, post-liver transplant Cyclosporine A 24-hour BP monitoring, FK506 (abst) arteriopathy on renal biopsy (abst) dietary fatty acids, GFR glomerular barrier function, azathioprine (abst) inhibits cell proliferation, TGF-f3 (abst) insulin sensitivity, BP (abst) monotherapy compared, azathioprine (abst) nephrotoxicity, arginine, modulated by NO nephrotoxicity, lipid peroxidation, vitamin E psoriasis, RAS, renal hemodynamics (abst) renal function, serum electrolytes (abst) Sandimmun-Neoral conversion (abst) vascular reactivity (abst) Cystathionine serum concentration, uremia (abst) Cystatin C, as marker of GFR Cytokines angiogenesis, extracellular proteolysis (abst)

1008

362 370 1481 1130 1426

977 998 611 1221 1006

987 975 1507 927 704 977 990 360 964 312 659

998 autoantibodies characterized, CRF (abst) 692 autocrine regulation human MC, GF (abst) 673 fibronectin production, MC (abst) 694 HgCl2-induced apoptosis, T-cell hybridoma (abst) 994 intraperitoneal, CAPD without peritonitis (abst) MC expression ICAM-1, MNC, IgA nephropathy 352 (abst) 671 MC synthesis complement, MHC antigen (abst) modulate human MC biosynthesis of C3 829 660 regulate U-937 monocyte MC adhesion (abst) 1403 urinary, complement SC5b-9, CD59, MGN Cytotoxic drugs, plasma exchange, amyloidosis (abst). . . . 1485

0 DDAVP vasodilator effects, EH (abst) 706 678 Decorin mRNA, TGF-13, DN (abst) 347 Defiazacort, NS, children, bone metabolism (abst) Degranulation inhibiting protein (DIP), uremia (abst) . . . . 672 Dehydration, WCH-CD endosome distribution, CD 675 (abst) 1775 Dermal angiopathy, HD patients 356 Desferrioxamine, plasma endothelin, HD (abst) 992 Dexamethasone, NOS, IL-lp, cAMP, MC (abst) 945 Dextran sulfate uptake by glomerular cells Dextrans induce IgAGN in rats (abst) 691 Diabetes Control and Complications Trial 1703 Diabetes insipidus (DI) intracranial calcifications (abst) 364 X-linked nephrogenic, gene mutation (abst). .. 344, 364, 991 Diabetes mellitus (DM) effect on PET with peritonitis 1760 674 glomerular changes, microalbuminuria (abst) 985 lipid profile, with/without nephropathy (abst)

pancreas/kidney transplant, UTI, NaHCO3 loss, 1001 theophyllin (abst) 981 patient/graft survival (abst) 975 post-transplant predisposition (abst) 782 renal hypertrophy and proto-oncogenes risk factors for RRT (abst) 366 secondary hyperparathyroidism, bone disease, uremia.. 1746 Diabetic nephropathy (DN) 1176 ACE gene polymorphism 49:S-55 AGEs induce ECM gene overexpression, GS 1726 antihypertensives, long-term therapy, GFR 970 de novo GS, post-transplant (abst) 678 dipyridamole effects (abst) 988 ESRD, epidemiology (abst) 935 experimental, cellular events in 673 fibronectin, cytoprotection, cultured MC (abst) 701 GBM heparan sulfate changes (abst) 351 glomerular HS-PG mRNA expression (abst) 674 glomerular proteinase, obesity (abst) 693 high glucose, GF gene, human MC (abst) 1703 intensive therapy 352 L-arginine, vascular function (abst) 985 lipid profile (abst) 357 lipoprotein(a) serum levels (abst) 907 plasma lipids, ACE inhibitors 231, 1781 progression 678 renal TGF-f3, decorin mRNA (abst) 673 TGF-f3 production, cultured MC (abst) Diadenosine polyphosphates 984 membrane voltage, MC (abst) 999 Na/H exchange, ADH, Ang II, CCD (abst) Dialysate 1768 AGE products, in vitro 1148 amino acid-based, malnourished CAPD patients 707 CA125, transport kinetics (abst) 369 calcium, zero solutions, CAPD (abst) 1537 commercial, TNFa mRNA, NF-kB DNA activity 705 complement in, children, CAPD (abst) 356 endotoxin concentration in 970 one-line method, HD (abst) 573 protein losses, reused dialyzers Dialysis. See also Continuous ambulatory peritoneal dialysis (CAPD); Hemodialysis; Peritoneal dialysis 1434 bone disease, PTH response congestive heart failure in 884 319 delivery, URR accuracy and Kt/V 1002 Eastern Germany (1993)/GDR (1989) (abst) 367 end-dialysis Na plasma water concentration (abst) 1732 LDL metabolism, uremia 365 new test for NO production (abst) 876 rHuIGF-1 impaired metabolic response 869 rHuIGF-1 pharmacokinetics 981 survival, diabetic/non-diabetic patients (abst) Dialyzers 966 AMBIO, compatibility compared (abst) 985 differing membranes, ischemic ARF (abst) 1218 elution technique, biocompatibility (abst) reuse and protein loss 573 Dietary. See also Salt 611 fatty acids, CsA therapy, GFR 973 protein, hypertension, PKD (abst) 353 protein, renal effects, early CRF (abst) 7 urinary protein concentration, health and CRF 1484 Digoxin intoxication, HD (abst)

1883

Subject Index: VoL 47

Dinucleotides, activate phospholipase C via AP4A 1007 receptors, MC (abst) 678 Dipyridamole and DN (abst) Distal acid-base transport, Nephrology Forum 333 Diuresis 664 organic osmolytes, urine concentration (abst) papillary pH gradient, CD urine, vasa recta (abst).. 681, 987 1806 DNA fragmentation, hypoxia, TAL, kidneys DNA synthesis, tubular salt load 1615 Donor kidneys 371 Alport syndrome carriers as living donors (abst) anti-HCV positive donors 236 360 living donor transplantation (abst) 1005 non-immunologic factors (abst) 996 pediatric, age-matching (abst) plasma/urine ET-1, living related donors/recipients 1008 (abst) Dopa, i.v., renal hemodynamics, normotensive ADPKD 1218 (abst) Dopamine 708 excretion, post-HLA identical transplant (abst) 973 PGE2 production, ET (abst) 986 Duplex sonography, essential hypertension (abst)

E E-selectin, Wegener's granulomatosis, SLE (abst)

989

ECTO-5'-nucleotidase (5'-NU), dual modulation (abst)... 699 Ectoenzymes, EC expression, signal transduction (abst) . . . 669 Elderly 962 antihypertensives, effects (abst) 962 antihypertensives, microalbuminuria (abst) 368 coronary risk assessment, pre-transplant (abst) 988 Electrophoresis, urine, interstitial nephritis (abst) Embryogenesis, human kidney, GATA-3 gene expression. 1597 661 Embryonic ureteric bud cell expression (abst) Enalapril

compared, nifedipine, BP, renal response, ET (abst)... 1216 erythrocytosis, post-transplant (abst) End-dialysis Na plasma water concentration (abst) End-stage renal disease (ESRD) aluminum hydroxide, serum Al (abst) cardiovascular disease DN (abst) HD and cardiovascular rhythms hyperhydration, arterial vessel walls (abst) LPS-induced IL-1f3 production/secretion registry program, HITEL Closed User Group program (abst) Endocrine function ischemic kidney (abst) sino-carotid denervation, ANP (abst) Endocytosis aprotinin, PT gp330 binds/mediates (abst) inhibition by specific antibodies (abst) transcytosis, albumin gold, peritoneal mesothelium. ... Endothelial cells 400 kD laminin chains expression (abst) dysfunction, EH (abst) dysfunction, microalbuminuria, IDDM (abst) TNF, ligand passing between receptors (abst) tyrosine kinases, PDGF, angiogenesis (abst) vascular, hemodynamic flow, NO synthesis (abst) VEGF, expression and receptors (abst) verocytotoxin receptor Gb3 induction (abst)

361 367 354 186

988 1443 964 1158 355 666 683 679 659 1274

697 1000 1223 677 660 695 660 705

Endothelin 1319 ACEi, prevent RF/death 687 Ang II, endothelial mitogenic response (abst) 684 cortical/juxtamedullary renal vasculature (abst) 1483 crush syndrome therapy (abst) human renal response, BP, enalapril, nifedipine (abst) . 1216 685 NO, gentamicin, MC activation (abst) 973 PGE2 production, dopamine (abst) 356 plasma, desferrioxamine, HD (abst) renal function 795 669 renin secretion, juxtaglomerular cells (abst) 1426 urinary, post-liver transplant Endothelin-1 (ET-1) 670 CsA, cell-cell interaction (abst) 676 endotoxin, glomerular resistance (abst) 996 fibrinolysis, prostaglandins, ARF (abst) induces mesangial cell COX-2 53 677 NO system, ischemic/reperfusion injury (abst) 1008 plasma/urine, before/after uninephrectomy (abst) plasma/urine, living related donors/recipients (abst) . . 1008 976 receptor subtypes, cirrhosis (abst) 666 renal function, L-arginine (abst) renal function, NO stimulation (abst) 707 renin release inhibition, juxtaglomerular cells (abst) . . . . 985 .

role in AIPKiiI (abst) tubular regeneration (abst) urodilatin, renal microcirculation (abst) Endothelin A (ETA) receptor antagonist expression in kidneys, SHR (abst) lupus nephritis Endothelium-dependent forearm vasodilation, CsA (abst) Endothelium-derived relaxing factor (EDRF), renal

995 693 1009 976

481 1221

microvessel vasodilation (abst) 684 Endotoxin 356 concentration in dialysate (abst) 676 glomerular resistance (abst) vasoconstriction, preglomerular juxtamedullary vessels 1216 (abst) 404 Engelbreth-Holm-Swarm (EHS) experimental GN Epidermal growth factor (EGF) 699 aminopeptidase N, 5'-NU, glomerular MC (abst) calcium channel blocker, ischemic renal injury (abst) . . . 343 490 receptor, CPK mouse kidney 774 receptor, tyrosine kinase activity 665 TGF-/3, neutral endopeptidase, VSMC (abst) Epithelial cells abnormal transport by, PKD and 720 Ca influx (abst) 972 Cl transport inhibitors 722 determinants of polarity 724 differentiation in ADPKD 716 distinctive adherence of E. coli (abst) 688 669 ectoenzymes, signal transduction (abst) 680 exogenous Na/K-ATPase 0-subunit (abst) 1682 generate metalloproteinases 659 GP280 and GP330 expression, endocytosis (abst) 677 IL-2ra, IL-lcw, INF (abst) 704 IL-8, INF-y, IL-la, TNF-a (abst) 721 maturation, solute transport mechanisms 705 MCP-1, IL-la, TNF-a (abst) membrane glycoprotein localized, PAN nephrosis 689 (abst) 694 molecular regulation, IL-8 production (abst) 968 1,25-D3 increases ICAM-1 (abst)

1884

PKD, abnormal regulation of cell growth polarized ion transport (abst) polarized molecular transport abnormalities, PKD polarized surface, lipids, proteins (abst) pro-inflammatory mechanisms (abst) produce enzymes, regulate ECM turnover (abst) renal, membrane surface of (abst) Epstein Barr virus (EBV) malignant lymphoma, post-transplant (abst) reactivated post-transplant, sero-diagnosis (abst) Erythrocytes accumulate S-adenosylhomocysteine, uremia Ca transport, hypercalciuria (abst) dysmorphic, histopathology of ON (abst) Erythrocytosis enalapril, post-transplant (abst) post-transplant predisposition (abst) Erythropoietin (EPO) acute renal failure (abst) with low dose i.v. iron, HD (abst)

Subject Index: Vol. 47

715 1001

724 658 677 673

679 980 1006 247 363 972 361

975 974 998

mRNA, oxygen-dependent expression, kidney (abst).... 694 683 nifedipine, RAS effects (abst) 984 response, hippuric acid, HD (abst) rHuEPO, LH kinetics/biopotency, men on HD (abst).. 1004 740 rHuEPO, stimulates angiogenesis Escherichia coli

turnover regulation, fibroblast enzymes, EC (abst) Extracellular nucleotides Ca, cortical TAL, Henle's loop (abst) modulate renal transport renal handling (abst) Extracellular osmolality, taurine efflux (abst) ExtracorpOreal circulation acute opiate intoxication (abst) for heart-lung bypass, ARE (abst) simultaneous adsorption/filtration (abst) Extracorporeal shock wave lithotripsy (ESWL) (abst)

673 700 1500 699 678 1007 343 971 345

F Factor B, MC synthesis, cytokines, MHC antigens (abst) . . 671 1419 Familial hypomagnesemia Fatty acids 611 dietary supplementation, CsA therapy, GFR polyunsaturated free, antidiuresis, vasopressin (abst). . . . 687

Fcy receptor III (CD16), human glomerular MC (abst)... 670 702 Felodipine derivative, hypoxic PT cell injury (abst) 984 Femoral head necrosis, post-transplant (abst) Fibrinogen serum levels, atherosclerosis, CAPD (abst). . . . 965 Fibrinolysis 997 peritoneal, mesothelial cells, CAPD (abst) 996 prostaglandin synthesis, ET-1, ARF (abst) 1483 therapy, renal vein thrombosis, NS (abst)

688 adherence, cultured human tubular EC (abst) 973 Fibroblast growth factor (FGF) host-specific uropathogenic virulence (abst) 986 PDGF, IL-1/3, NOS, MC (abst) megalocytic interstitial nephritis (abst) podocyte mitosis, cell division (abst) verocytotoxin-producing, hemolytic uremic syndrome 1222 podocytes, membranous nephropathy (abst) (abst) Fibroblasts Essential hypertension (EH) 978 ambulatory BP monitoring, salt intake (abst) ECM-degrading proteinases/inhibitors (abst) 1216 AT-i receptor antagonist SR 47436 (abst) enzymes, regulate ECM turnover (abst) IL-i 706 DDAVP vasodilator effects (abst) 986 IL-i, IL-6, IL-8 duplex sonography and age (abst) interstitial renal fibrosis (abst) 1000 human endothelium function (abst) 366 hyperfiltration, salt intake (abst) molecular biology of origins (abst) 992 Na intake, albuminuria (abst) transdifferentiation, renal fibrogenesis (abst) 703 Fibromuscular dysplasia causes RAS (abst) renal/systemic response to RAS (abst) 1217 Fibronectin renin-inhibition, natriuresis (abst) Essential mixed cryoglobulinemia (EMC) cytoprotection by silibinin (abst) HCV antigen immune response, HLA typing (abst) .... 367 isoforms, anti-Thy-i nephritis (abst) 618 production, cytokines, MC (abst) nephritis, long-term survival 611 Evening primrose oil, GFR, CsA 5HTia receptor agonist (Flesinoxan) (abst) 969 5 '-nucleotidase (5 '-NU) Exercise-induced K changes, CRF (abst) dual modulation (abst) Exit-site infections 982 local antibiotic treatment (abst) upregulation, EGF, human MC (abst) sulcus fluid flow rate, PD (abst) 994 FK506 24-hour BP monitoring, CsA (abst) Extracellular matrix (ECM) 725 abnormalities of, PKD and metabolic changes, post-transplant (abst) 49:S-55 renal function, serum electrolytes (abst) AGE, ECM gene overexpression, DM, GS 49:S-4 basement membrane structure salvage, OKT3 resistant rejection (abst) 49:S-48 cell-cell cross-talk, interstitial renal fibrosis urinary ET, post-liver transplant 363 Flesinoxan, renal function (abst) cell specific regulation, TGF-/3 (abst) 49:S-15 Focal segmental glomerulosclerosis (FSGS) crinopexy, extracellular GF regulation 1039 clinicopathology, adults (abst) degradation by PA/plasmin/MMP-2 cascade GS progression and 49:S-39 distribution of lesions, adults/children 49:S-51 models of nephron reduction early morphological changes (abst) proteinases, human renal fibroblasts (abst) 990 podocytes, adhesive phenotype (abst) 49:S-12 prolonged NOS blockade (abst) remodeling, metalloproteinases, PAs renal disease progression, chemokines 49:S-44 Forearm vasculature TGF-/3 mediates GS 49:S-59 hypertension, muscarinic receptors (abst) 49:S-19 TGF-f3 overview hypertension, vasodilation, CsA (abst) 49:S-8 400 kD laminin chains, ET cells (abst) transmembrane signaling

695 689 677 990 673 837 845 673 1002 1002 1219

673 698 673 668 699 699 977 977 977 975 1426

668 348 1690 348 689 696 705 1221

697

Subject Index: Vol. 47

Furosemide Na and Cl-dependent taurine reabsorption (abst) tubular hypertrophy, IGF-1 and IGFBP-1 tubular site of action (abst)

997 818 682

G G-proteins, organic osmolyte efflux, CD cells (abst)

Gamma-globulin, i.v., renal effect (abst) GATA-3 gene expression, kidney embryogenesis Genetics ACE gene and DN adenovirus-mediated gene transfer Ang2 receptor mRNA antisense angiotensinogen transgenic mice

996 351 1597

1176 322 1095 1638

antisense oligonucleotides, organ development (abst)... 693 biphasic TNF-a in MRL-lpr mice 122 1199 COL4A3 mutation, Alport syndrome GATA-3 expression, human kidney embryogenesis.... 1597 Gitelman's syndrome Henoch-Schonlein (abst) HLA-DRB1, PKD-1 gene analysis, adult PKD (abst) ... human renal development (abst) localization of Mn-SOD mRNA, nephron malignant hypertension model

547 364 996 661

536 529

mutation, hereditary nephrogenic DI (abst)... 344, 364, 991 new mouse PKD mutant 552 986 novel gene products, renal organogenesis (abst) polycystic kidney disease (PKD) prenatal diagnosis of Alport syndrome renal genes, kidney differentiation/disease (abst) Rf-1 gene identification (abst) Senior-Loken syndrome (abst) targeted oncogenesis, renal cell lines transferrin gene expression WiIm's tumor protein expression (abst) Gentamicin hypercalciuria, nephron site (abst) MC activation, ET, NO (abst) PAF in mesangial cells Gitelman's syndrome calcium absorption (abst) genetics Glomerular basement membrane (GBM) anti-GBM Ab (abst) antibody deposits, immune complexes (abst) heparan sulfate changes, DN (abst) heparan sulfate staining, lupus nephritis (abst) Glomerular capillaries albumin binding to wall morphometry, reflux nephropathy, children Glomerular cells human epithelial, metalloproteinases molecular regulation, IL-8 production (abst)

Glomerular filtration rate (GFR) allografts, pre/post-transpiant (abst) cystatin C as marker dietary fatty acids, CsA therapy elevation, glucagon, cAMP, urea (abst) endotoxin, hemodynamic resistance (abst) inulin clearance, without urine collection (abst) long-term antihypertensive therapy, DN Glomerular function analysis of biopsy cases (abst) blood flow control and NO (abst) cAMP-dependent protein kinase (abst)

728 327 669 702 662 388 1068 661

667 685 1346

364 547 350 1006 701 701 1031

1108 1682 694

360 312 611 685

676 993 1726 346 676 688

CsA, azathioprine (abst) Glomerular hypertrophy GS in proteinuric rats (abst) hyperplasia, isolated glomeruli (abst) Glomerular injury, ACEi, mesangial volume (abst) Glomerular labeling, nephrogenesis (abst) Glomerular permeability ANP, natriuresis, albuminuria, NS (abst) MCD, vasoactive human plasma factor (abst) PGE1, proteinuria, renal hemodynamics, GN (abst) ... Glomerular proteinase activity, DM, obesity (abst) Glomerular proteolysis, protein synthesis, GS (abst) Glomerulonephritis adults, analysis of biopsy cases (abst) ANCA-associated anti-MPO, ischemia/reperfusion injury apoptosis (abst) bacterial LPS-induced, INF-y (abst) crescent formation, anti-GBM Ab (abst) crescentic, /3 /33 integrins, ICAM-1, VCAM-i counter-receptors (abst) crescentic, IL-ira halts established dysmorphic erythrocytes, histopathology (abst) EHS experimental EMC, long-term survival ICAM-1, /31 integrin, MC (abst) IgA mesangial, induced by dextran (abst)

INF-c therapy, HBV (bst)

L-arginine, proteinuria, hypertension (abst) lipoxin A4 synthesis .

1885 1221

691 691

676 661

993 1218 1007

674 1009 346 193 1121

657 974 350 370 1303 972 404 618 352 691 349 1007 1295

membranous, urinary CD59, SC5b-9 and cytokines.... 1403

methicillin-resistant S. aureus infection 207 ornithine metabolism (abst) 678 1007 PGE1, proteinuria, renal hemodynamics (abst) 114 proliferative, apoptosis in 688 proliferative, MC apoptosis (abst) secondary membranoproliferative, Nephrology Forum .. 643 undifferentiated connective tissue disease (abst) 987 Glomerulosclerosis AGEs induce ECM gene overexpression, DM 49:S-55 Ang II modulates PDGF 131 49:S-39 collagen, collagenase mRNAs, progression 970 de novo diabetic GS, post-transplant (abst) 698 differential expression, collagen subchains (abst) 677 FGF, podocytes, membranous nephropathy (abst) 348 FSGS, adults, clinicopathology (abst) 1690 FSGS, adults/children 348 FSGS, early morphological changes (abst) 689 FSGS, pódocytes, adhesive phenotype (abst) 696 FSGS, prolonged NOS blockade (abst) 691 glomerular hypertrophy, proteinuria (abst) 1009 glomerular proteolysis, protein synthesis (abst) MC collagen, insulin 25 MC growth abnormalities 106 691 PAN, MCP-I, TGF-(3 (abst) 986 podocyte injury (abst) 49:S-59 TGF-/3 mediates 442 uninephrectomized female analbuminemic rats Glomerulus 686 adenosine-hypersensitivity, low-Na rats (abst) 688 cationized Ig aggregates (abst) 1630 charge selectivity, horseradish peroxidase 945 dextran sulfate uptake, ultrafiltration 689 EC membrane glycoprotein, PAN nephrosis (abst) 698 fibronectin isoforms, anti-Thy-i nephritis (abst) 351 lipid peroxidation, high glucose (abst)

1886

Subject Indes: VoL 47

500 1690 696 689

1002 ANP, brain and C-type natriuretic peptides (abst) 1481 antiphospholipid antibodies (abst) 999 bacterial infection, HCV, HBsAg, CD14 (abst) 993 BIA evaluation, body fluid composition (abst) 1434 ultrastructural changes, microalbuminuria, DM (abst)... 674 bone disease, PTH response 687 983 bone mass reduction dynamics (abst) vasotocin receptors, phosphoinositidase C (abst) 685 1741 Glucagon, GFR elevation, cAMP, urea (abst) [Ca2I1 verapamil, PMNL function Glucocorticoids 356 calcium-free, hypercalcemia management (abst) 802 1443 K transport, Henle's loop cardiovascular rhythms, ESRD 680 967 Na/K-ATPase gene transcription (abst) coronary artery calcifications (abst) 1669 988 renal NaHCO3 cotransporter coronary risk factors (abst) Glucose 1775 dermal angiopathy 352 356 high, ICAM-1, f31 integrin, MC (abst) desferrioxamine, plasma endothelin (abst) 351 1218 high, lipid peroxidation, isolated glomeruli (abst) dialyzer elution technique (abst) 1057 high, PKC isoforms, VSMC 1484 digoxin intoxication (abst) 693 MC, GF gene expression (abst) 970 dose, nutritional parameters (abst) Glutamine 987 electric bio-impedance (abst) 299 exogenous, tubular cell growth 998 EPO with low dose i.v. iron (abst) 96 metabolism, regulation by OK cells 911 HCV nosocomial infection 262 Glycine-induced hyponatremia, post-prostatectomy 973 high serum levels soluble CD14 (abst) Glycoprotein, 43 dDal membrane, PAN nephrosis (abst).. 689 984 hippuric acid concentration, EPO (abst) Glycosaminoglycans (GAG) 1412 interferon therapy, HCV 1224 suiphated, proteinuria, overt nephropathy (abst) 1004 LH kinetics/biopotency, rHuEPO, men (abst) 690 synthesized, MC, compared proteoglycans (abst) 1000 low turnover osteopathy (abst) Glycosylation 1453 math model for f32-M deposits 365 abnormal IgA, integrin expression on MC 354 metabolic acidosis anion gap patterns (abst) 365 altered IgA, IgA nephropathy (abst) 559 monokine production Goodpasture's syndrome 357 morbidity/mortality factors (abst) 698 autoantibody-antigen binding (abst) 1722 mortality time course, Uruguay 690 autoreactive T-cell clones (abst) 358 nutritional comparison, CAPD (abst) 404 EHS type IV collagen, GN 970 one-compartment (blood) UKM (abst) 350 positive circulating anti-GBM antibodies (abst) 970 one-line method (abst) gp330 984 pantoprazole, pharmacokinetics (abst) 679 binds/mediates endocytosis of aprotinin (abst) 977 Permcath complications (abst) 689 cloning/sequencing of cDNA coding (abst) 972 polyamines in RBC and plasma (abst) Granulocyte inhibitory protein (GIP), uremic toxicity 988 672 post-contrast media application (abst) (abst) 363 1218 removal, NOS-blocking compounds (abst) Granulocytopenia, biphasic, post-OKT3 (abst) 355 serum K concentration, hyperkalemia (abst) Granzyme A, B proteins, cytotoxic lymphocytes, rejection .. 70 1000 serum phosphate, post-parathyroidectomy (abst) Growth factors 359 serum soluble HLA-I antigen levels (abst) 692 autocrine regulation human MC, cytokines (abst) 971 719 simultaneous adsorption/filtration (abst) in cell proliferation 1482 49:S-15 single/double pump, one/two needles (abst) crinopexy, extracellular regulation 994 688 staphylococcus-effective prophylaxis, CRIs (abst) deprivation, proliferative GN (abst) 359 tuberculosis manifestations (abst) 693 high glucose, gene expression, human MC (abst) 1481 UV irradiation, disinfection of water (abst) Growth hormones $6 1658 vascular access, clotting, SLE (abst) IGF-1 in ARF $6 1374 vascular access, coagulation abnormalities (abst) IGF-1 mRNA in GH-treated uremic bone 356 vascular access, measurement methods (abst) 464 Guanidino compounds, renal insufficiency $6 696 vascular access, seroma, PTFE grafts (abst) Guanylyl cyclase systems, in glomeruli (abst) 1364 vascular access, thrombosis 964 zinc protoporphyrin, endogenous iron (abst) 989 H Hemofiltration, continuous, ARF (abst) 1219 707 Hemoglobin, carbamylated, index of uremia (abst) Hantavirus nephropathy (abst) 638 Hemolytic uremic syndrome Heat disinfection, membranes 342 Heat shock proteins (HSP) clinical study (abst) 1222 986 HSP 70, mRNA expression, PT cells (abst) verocytotoxin-producing E. coli (abst) 990 Hemoperfusion localization, kidney (abst) 359 1752 renal ischemic injury paraquat intoxication (abst) 988 Heavy metal intoxication propafenone intoxication (abst) 365 971 Hemorrhage, pulmonary, ANCA-positive vasculitis (abst) . early urinary detection (abst) 1677 Hemorrhagic fever with renal syndrome (HFRS) rBAT-induced amino acid transport 350 1336 adhesion molecules (abst) Heme-induced cytoresistance 353 NO role (abst) Heme protein-mediated renal injury, 21-aminosteroids.... 592 Henoch-Schonlein Hemodialysis. See also Dialysate; Membranes, hemodialysis purpura nephritis, compared, IgA nephropathy (abst)... 349

regulation, iNOS expression scierosed, adults vs. children soluble/particulate guanylyl cyclase systems (abst) transplantation, genetically-engineered MC (abst)

Subject Index: Vol. 47

susceptibility, HLA-DRBI gene analysis (abst) Heparan sulfate proteoglycans

364

Mg II, human MC (abst)

701

GBM, lupus nephritis (abst) GBM changes, DN (abst) perlecan modulates MC (abst)

701

Heparin dosages/targets, neuropathy (abst) extracorporeal LDL precipitation (HELP) (abst) lowers blood pressure

701 690 689 999 1017

thrombocytopenia, anaphylaxis, post1003 parathyroidectomy (abst) Hepatitis, chronic viral and CRF 1231 Hepatitis B virus (HBV) 999 CD14, HCV, bacterial infections, HD (abst) 1003 East German dialysis centers (1989-1993) (abst) 349 INF-a therapy, GN (abst) membranous nephropathy, INF-a 225 1001 post-transplantation (abst) 1483 vaccine non-responders, rIL-2, uremia (abst) Hepatitis C virus (HCV) 367 anti-HCV antibodies, cryoglobulinemia (abst) anti-HCV positive allograft recipients, HBsAg (abst) . . . 361 anti-HCV positive donors 236 367 antigens, HLA typing, cryoglobulinemia (abst) CD14 and HBsAg, bacterial infections, HD (abst) 999 interferon therapy, HCV infection, HD 1412 nosocomial infection 911 1001 post-transplantation (abst) prevalence, mode of transmission (abst) 357 Hepatocytes growth factor as a renotrophic factor 718 1522 metabolism, CRF Heymann nephritis 1604 active, complement C6 689 eDNA coding for gp330 (abst) 432 receptor-associated 39/45 kD protein renal injury, NOS inhibition (abst) 692 684 High density lipoprotein (HDL), RA dilation (abst) Hippurate, renal clearance, renal blood flow (abst) 1220

Hippuric acid concentration, EPO response, HD (abst)... 984 HITEL Closed User Group program, ESRD registry (abst) HLA DQB1 *0301 allele, primary IgA nephropathy (abst)

355

1482

HLA-DRB1 gene analysis Henoch-Schönlein 364 PKD-1 gene, adult PKD (abst) 996 HLA typing essential mixed cryoglobulinemia, HCV antigen (abst) . . 367 963 graft related antibodies (abst) 359 HD, post-transplant (abst) 708 Na homeostasis, dopamine, post-transplant (abst) Homocysteine 247 generates S-adenosylhomocysteine 964 serum concentration, uremia (abst) Horseradish peroxidase, glomerular charge selectivity. . . . 1630 Hyaluronate hydrolases, vasopressin, urinary bladder 683 (abst) 356 Hypercalcemia, calcium-free hemodialysis (abst) Hypercalciuria 363 erythrocyte Ca transport (abst) 1419 familial hypomagnesemia 667 gentamicin, nephron site (abst) 579 Hypercholesterolemia, LDL, nephrotic dyslipidemia

1887

366 Hyperfiltration, salt intake, EH (abst) Hyperkalemia 969 32-adrenoceptor-agonist therapy (abst) metabolic acidosis, NaHCO3 insulin in glucose (abst). . . 355 serum K concentration, HD (abst) 355 Hyperlipidemia albumin and apo B degradation 421 579 LDL metabolism, nephrotic dyslipidemia uninephrectomized female analbuminemic rats 442 1482 Hyperoxaluria type I, primary (abst) Hyperparathyroidism 370 persistent, new markers, post-transplant (abst) 965 persistent, post-allotransplant (abst) 1746 secondary, bone disease, uremia, DM Hypertension. See also Essential hypertension Mg II blockade, 2-K 1-C rats 1394 973 chloride and protein intake, PKD (abst) CsA, endothelium-dependent forearm vasodilation 1221 (abst) 1007 L-arginine, proteinuria, GN (abst) lack of insulin effect, mesangial cells 891 529 malignant, genetic model microalbuminuria, non-diabetics, concomitant diseases 962 (abst) microalbuminuria, non-diabetics, with/without end962 organ injury (abst) 78 Na/H antiporter (NHE-1 isoform), VSMC, SHR 981 nephrosclerosis, aortic valve regurgitation 998 post-transplant (abst) 1002 primary, ADPKD renal prognosis (abst) primary, muscarinic receptors, forearm vascular bed 705 (abst) renal function, black NIDDM subjects 1697 169 salt sensitivity, vascular compliance systemic, race and allograft survival 1136 unilateral small kidney, RA occlusion (abst) 982 964 vessel wall properties, post-transplant (abst) 566 Hypertriglyceridemia in nephrotic syndrome 217 Hyperventilation, K response, respiratory alkalosis Hypocalciuria 547 Gitelman's syndrome 364 Gitelman's syndrome, Ca absorption (abst) Hypokalemia 547 Gitelman's syndrome 969 post-32-adrenoceptor-agonist therapy (abst) Hypomagnesemia familial

Gitelman's syndrome Hypoxia. See Injury, renal

1419

547

I Ig aggregates, cationized, glomeruli (abst) IgA nephropathy allograft recipients, living-related donors (abst) altered glycosylation of IgA (abst) clinical perspectives

688 361 365

377

compared, Henoch-Schonlein purpura nephritis (abst).. 349 familial (abst) ICAM-1, MC, cytokines, MNC (abst) mesangial GN induced by dextrans (abst) primary, HLA DQB1*0301 allele (abst) prognostic factors (abst) red cell Na/Li countertransport (abst) smooth muscle a-actin, MC (abst) T-cell receptors

367 352

691 1482 349 366 364 177

1888

Subject Index: Vol. 47

671 IgG complexes, MC binding, Clq complement (abst) 976 Imidazoline receptor agonists, renal action Immune complexes, glomerular deposits, isoelectric point 1006 (abst) Immunoglobulin light chains, PMN functions, uremia 969 (abst) Immunosuppression 977 24-hour BP monitoring, FK506 and CsA (abst) 980 cancer, associated factors (abst) 370 CsA blood trough level variability (abst) 975 CsA monotherapy, compared azathioprine (abst) 370 CTLA4Ig, allograft survival (abst) 241 CTLA4Ig, as novel antirejection strategy 980 EBV, malignant lymphoma, post-transplant (abst) 979 metabolic risk factors, post-transplant (abst) renal function, serum electrolytes, CsA, FK506 (abst). . 977 990 Sandimmun-Neoral conversion (abst) 361 T-cell subset changes, peripheral blood (abst) 998 Immunotactoid-like glomerulopathy (abst) 342 Indomethacin, renal hemodynamics, neonates (abst) Infection 999 bacterial, HCV, HBsAg, effect on CDI4 (abst) 982 exit-site, local antibiotic treatment (abst) 994 exit-site, sinus-tract, sulcus fluid flow rate (abst) 638 heat disinfection of HD membranes 207 S. aureus, methicillin-resistant, GN 994 S. aureus, prophylaxis (abst) 603 transfer across HD membranes 1005 UTI, bacterial spectrum, post-transplant (abst) 1001 UTI, post-pancreas/kidney transplant, DM (abst) 968 Infradian bioperiodicity, urinary enzymes (abst) Injury, renal 702 calcium channel blockers, anoxic PT cells (abst) 702 cell, Ca, anoxic PT cells (abst) 691 chronic, prolonged metabolic acidosis (abst) 676 glomerular, ACEi, mesangial volume (abst) 592 heme protein-mediated, 21-aminosteroids 1087 hypoxic, PT, plasmalogen phospholipid hydrolysis 628 hypoxic, PT obstruction, ATN, cytoresistance ischemic, calcium channel blocker, c-fos, EGF (abst) . . . 343 1752 ischemic, heat shock proteins 986 ischemic, heat shock proteins (abst) 343 oxidant-induced, proximal tubules, Ca (abst) 965 PT, BBM proteins as markers (abst) 677 reperfusion, ET-1, NO system (abst) 1121 reperfusiori, ischemia, anti-MPO GN 677 reperfusion, ischemia, ET-1, NO (abst) 1222 reperfusion, ischemia, 21-aminosteroids (abst) 686 Inositol lipid signalling system (abst)

Insulin hyperkalemia, metabolic acidosis, NaHCO3 (abst) mesangial cell collagen mesangial cells, SHR sensitivity, BP, CsA therapy (abst) sensitivity, calcitriol i.v. in uremia

vasoconstriction, renal resistance arteries (abst) Insulin-dependent diabetes mellitus (IDDM) endothelial dysfunction, microalbuminuria (abst) prorenin, microalbuminuria (abst) Insulin-like growth factor-i (IGF-1) aminoguanidine inhibition, NOS (abst) IGFBP-1, tubular hypertrophy mRNA in GH-treated uremic bone renal growth hormone, ARF rHuIGF-1, metabolic response, dialysis

355

25 891

987 200 997 1223 1224

685 818 1374 1658 876

rHuIGF-i, pharmacokinetics, dialysis Integrins cell polarity, PKD cell lines crescentic GN (abst) MC expression, IgA modulates (abst) Intercellular adhesion molecule-i (ICAM-1) counter-receptors, crescentic GN (abst) hemorrhagic fever with renal syndrome (abst) human allograft rejection, VCAM-1 interstitial nephrosclerosis, MCP-1 (abst) leukocyte, renal vasculitis, IL-la (abst) leukocyte, renal vasculitis, VCAM-i (abst) MC, 31 integrin, GN (abst) MC, f31 integrin, high glucose (abst) MC, cytokines, MNC, IgA nephropathy (abst) 1,25-D3 increases, human TEC (abst) Wegener's granulomatosis, SLE (abst)

Interferon-a (INF-a) therapy, HBV-associated GN (abst) therapy, HBV membranous nephropathy therapy, HCV, hemodialysis upregulation, IL-2ra, proximal ET (abst) Interferon-y (INF-y) bacterial polysaccharide GN (abst) mesangial proliferative nephritis NS, children, CsA, steroids, IgE-rIl (abst) PTEC production human IL-8 (abst) Interleukin-1 (IL-i) chronic allograft rejection (abst) cyclooxygenases, prostacyclin, TxA2 MC (abst) human kidney fibroblasts IL-8, IL-6 in human MC, cAMP (abst) receptor antagonist halts crescentic GN synthesis, IL-6, IL-8 production, fibroblasts

Interleukin-la (IL-la)

869 726 370 365

370 350 1383 692 672 363 352 352 352 968 989 349 225 1412 677 974 62 346 704 361 686 837 687 1303 845

leukocyte, renal vasculitis, ICAM-1, VCAM-1 (abst). . . . 672 704 PTEC production, IL-8 (abst) 705 PTEC production, MCP-1 (abst) Interleukin-1 13 (IL-iJ3) 587 bone disease, f32-M, prostaglandins 992 induced NOS, dexamethasone, cAMP, MC (abst) 695 induced NOS, FGF, PDGF, MC (abst) lipopolysaccharide-induced, mononuclear cells, ESRD . 1158 990 NOS expression by NO in MC (abst) 1354 tyrosine phosphorylation, COX II expression Interleukin-2 (IL-2) 708 receptor, anti-IL-2R MoAb, rejection (abst) 677 receptor, proximal tubular EC (abst) rIL-2, uremia, HBV vaccine non-responders (abst). . . . 1483 Interleukin-6 (IL-6) 694 LPS and cAMP induce gene expression (abst) 282 peritoneal mesothelial cell synthesis 559 production, chronic HD patients 845 production, cultured kidney fibroblasts Interleukin-8 (IL-8) 694 molecular regulation, human glomerular EC (abst) 845 production, cultured kidney fibroblasts 704 PTEC, IL-la, INF-y, TNF-a (abst) Interleukin-lO (IL-b), production, chronic HD patients. . . 559 973 Interstitial cell culture, Na transport, CD cells (abst) Interstitial nephritis 986 megalocytic, E. coli bacteremia (abst) 988 urine electrophoresis (abst) 692 Interstitial nephrosclerosis, pathogenesis (abst) 703 Interstitial rejection, biopsy findings (abst)

Subject Inde,: Vol. 47

Interstitial renal fibrosis cell-cell cross-talk fibrogenesis, transdifferentiation in (abst)

49:S-48 1002 837, 845 673 1546 1005

human, cytokines and human, MAB TN2O, pathomechanisms (abst) inflammation, proteinuria tissue expression factor (abst) Intracerebroventricular ANP immunoneutralization 682 (abst) Intracranial calcifications, X-linked nephrogenic DI 364 (abst) Intrapelvic pressure measurement, acutely dilated pyelon 964 (abst) 1806 Intrarenal apoptosis from hypoxia Intrarenal resistance index, sonography, EH, age (abst) . . . 986 Inulin clearance, GFR, without urine collection (abst) . . . . 993 983 Iodine monitoring, contrast medium, RI (abst) Ion currents, extracellular ATP and UTP, membrane 700 voltage (abst) Ion transport 1005 12(R)-HETE, colon (abst) 1001 polarized, transformed EC migration (abst) 988 lopentol, pharmacokinetics with RI (abst)

Iron low dose i.v. therapy, with EPO, HD (abst) transferrin gene expression zinc protoporphyrin as marker, HD (abst) Ischemia, renal ARF, differing dialyzer membranes (abst) calcium channel blockers, Ca, PT cells (abst) calcium channel blockers, Na/K-ATPase (abst) DNA fragmentation, TAL, kidneys endocrine function, ischemic kidney (abst) ET-1, NO system, reperfusion injury (abst) heat shock proteins do not prevent injury

998 1068 964 985

702 345 1806 666 677 1752 986

HSP7O mRNA, protects PT cells (abst) organic osmolytes, amino acids, cortex/outer medulla (abst) reperfusion injury, anti-MPO GN 21-aminosteroid effects, reperfusion injury (abst) Ischemic heart disease, Lp(a), CAPD (abst)

991 1121

1222 357

K permeability disorders, chronic RI (abst) K plasma response, acute respiratory alkalosis K serum concentration, hyperkalemia, HD (abst)

Juxtaglomerular cells Cl stimulates renin secretion (abst) ET-1 inhibits renin secretion (abst) ET effects, renin secretion (abst) RAS, NOS distribution (abst) renin release, oxidized LDL, Lp(a) second messenger control, renin mRNA (abst)

675 985

669 670, 964 45 669

K conductance of PT, cytosolic pH regulation (abst) exercise-induced changes, CRF (abst) hyperkalemia, p2-adrenoceptor-agonists (abst) hypokalemia, post-132-adrenoceptor-agonists (abst)

965

969 969 969

K channels

brain, expression patterns, transfected in MDCK cells (abst) Ca-activated, apical membrane, human colonic T84 cells (abst) embryonic ureteric bud cell expression (abst) K deprivation, salt restriction, calciuria K loading, PT, loop of Henle Na, K reabsorption (abst)

658 680 661

899 667

974 217 355

K transport proximal convoluted tubule, fluid reabsorption (abst). in TAL and glucocorticoids Kallikrein, HCO3 excretion regulation (abst) kD laminin chains expression, ET cells (abst)

697 802 681

697

L L-arginine 1458 arginine decarboxylase in the kidney CsA toxicity, modulated by NO 1507 1458 decarboxylase in the kidney ET-1, effects on renal function (abst) 666 1515 nitric oxide, captopril, CRF 353 NOS inhibition, central/peripheral pressor (abst) 464 production, guanidino compound metabolism, RI 1007 proteinuria, GN, hypertension (abst) 1252 reabsorption, tubuloglomerular responses 352 vascular function, diabetes (abst) 682 vasopressin, natriuretic effect (abst) Lactate-buffered CAPD fluids, mesothelial cell function. . . 282 Lactatemia, post-f32-adrenoceptor-agonist therapy (abst) . . 969 Latent transforming growth factor-n binding protein 733 (LTBP), localization 1004 Left ventricular hypertrophy, post-transplant (abst) Leukocytes infiltration, renal vasculitis, ICAM-1, VCAM-1, IL-la 672 (abst) infiltration, renal vasculitis, ICAM-1, VCAM-1 (abst). . . 363 660 influx, nephrotoxic nephritis (abst) Lipid-lowering agents, rhabdomyolysis, post-transplant 362 (abst) Lipid peroxidation CsA nephrotoxicity, vitamin E 927 351 high glucose, isolated glonieruli (abst) 663 inhibits Na/K-ATPase, PT (abst) 681 intracellular pH, PT cells (abst) 999 during LDL apheresis by HELP (abst) Lipids

J

1889

plasma, DN, ACEi profile, type I DM (abst) profile improvement, polyamide membrane HD (abst) . sorting to polarized epithelial surface (abst) Lipocortin-l, inhibits human MC proliferation (abst) Lipopolysaccharides IL-/3 production/secretion macrophages, dialysate, TNFa mRNA, NF-kB activity . Lipoprotein(a) atherosclerosis, CAPD patients (abst) cholesterol loading, MC (abst) endothelium-dependent RA dilation, HDL (abst) ischemic heart disease, CAPD (abst) LDL, renin release, juxtaglomerular cells lipid profiles, CRF, post-transplant (abst) serum levels, DN (abst) Lipoproteins albumin and apo B degradation serum, post-transplant (abst) uninephrectomized female analbuminemic rats Lipoxin synthesis in GN Lithium clearance, analysis by micropuncture reabsorption, vasopressin, site of action (abst)

907 985 1485

658 351

1158 1537

965

989 684 357 45 357 357 421 1005 442 1295

1023 683

1890

Subject Index: Vol. 47

Liver cell metabolism in uremia 1522 976 Liver cirrhosis, renal ET-1 receptor (abst) Liver fibrillary deposits, immunotactoid-like 998 glomerulopathy (abst) Liver transplantation, urinary endothelin, CsA, FK506. . . 1426 LLC-PK1 cells 395 mercury toxicity NH4C1-induced hypertrophy, lysosomal cysteine 1003 proteinases (abst) 1003 TGF-pl, proteinase activity (abst) 343 transport system, cisplatin effects (abst) 663 ultrastructure and water transport (abst) 992 Loop diuretics, torasemide (abst) Loop of Henle 681 extracellular NaC1 modulates adenosine (abst) 700 extracellular nucleotides, Ca, cortical TAL (abst) 997 furosemide, taurine reabsorption (abst) 802 glucocorticoids, K transport 667 medullary hypotonicity, HCO3 transport (abst) 667 Na, K reabsorption with K loading (abst) 667 Na reabsorption, measurement methods (abst) 789 Na transport in ATL Lovastatin, PDGF-induced DNA synthesis, MC (abst).... 351

Low blood flow method, vascular access recirculation measurement (abst) Low density lipoproteins (LDL) apheresis, lipid peroxidation during, HELP (abst) Lp(a), renin release of JG cells stimulates MC proteoglycans (abst) Low-density lipoproteins (LDL) metabolism, uremia, dialysis nephrotic dyslipidemia lpr gene, biphasic TNF-a in MRL-lpr mice Lung transplantation, renal function after (abst) Lupus nephritis ETA receptor antagonist heparan sulfate staining, GBM (abst) PAl-i expression TXA2 synthase inhibition Luteinizing hormone, kinetics/biopotency, rHuEPO, men

on HD (abst)

Lymphocytes express granzyme proteins, rejection kidney cellular infiltration, neuraminidase

Lymphoma post-transplant (abst) Lysosomal cysteine proteinases, NH4C1-induced cellular hypertrophy (abst)

M Macrophages kidney cellular infiltration, neuraminidase LPS-stimulated, dialysate, TNFa mRNA, NF-kB activity

peritoneal, characterization, PD (abst) Macula densa cells apical sodium proton exchange Na:2Cl:K cotransport, luminal chloride Magnesium renin, Na excretion, relative heart weight (abst) transport, cell membranes, RI (abst) Major histocompatibility complex (MHC) alleles, systemic vasculitis

356 999 45

690 1732 579 122 704 481 701

148 1168

1004

70 88 988 1003

88 1537 1481

746 752 995 983

294

antigens, complement factors, MC, cytokines (abst) . . . . 671 529 Malignant hypertension, genetic model Matrix metalloproteinases (MMP) 659 expression and TIMP, ARPKD (abst)

1682 1039 49:S-12 715

generated by human glomerular EC PA/plasmin cascade, ECM degradation remodel ECM, plasminogen activators Maturation arrest hypothesis, PKD MDCK cells CD intercalated cell properties (abst) cell volume during migration (abst)

679 697 395

mercury toxicity

Medullary CD, acid-base transport, Nephrology Forum... 333 667 Medullary hypotonicity, HCO3 transport (abst) 668 Medullary interstitium, NaCl, prostaglandins (abst) Medullary nephrocalcinosis, sonography, adults (abst) .... 995 986 Megalocytic interstitial nephritis, E. coli (abst) 1219 MELAS and renal failure (abst) Membranes, hemodialysis AMBIO dialyzer biocompatibility (abst) bacterial product transfer f32-M adsorption (abst) differing, ischemic ARF recovery (abst) drug kinetics, PAN membrane (abst) interaction, adhesion proteins oxygen radicals, biocompatibility (abst) polyamide, lipid profiles (abst) polysulphone dialyzers, heat disinfection polysulphone dialyzers, reuse, protein loss Membranoproliferative GN, secondary, Nephrology Forum Membranous glomerulonephritis undifferentiated connective tissue disease (abst) urinary CD59, SC5b-9 and cytokines Membranous nephropathy clinical review (abst) FGF, podocyte injury (abst)

966 603

356 985

982 1115 995 1485

638 573 643

987 1403

349 677 225 1218 1130 395

HBV, INFa therapy idiopathic, urinary excretion J32-M (abst) progressive, cyclosporine trial Mercury toxicity in kidney cells Mesangial cells adult proliferation, verapamil (abst) ANP, growth suppression, TGF-j3 (abst) apoptosis (abst) ATP, phospholipase C, c-fos, P2u-receptors (abst) autocrine regulation, cytokines, GF (abst) biosynthesis, C3

C-type natriuretic peptide receptors (abst) Ca-dependent Cl conductance (abst) CD44 shedding, neutrophil proteases (abst) cholesterol loading, Lp(a) (abst) collagen, insulin, nodular sclerosis complement factors, cytokines, MHC antigen (abst) . cytokines modulate fibronectin (abst) diadenosines, membrane voltage (abst) ectoenzyme expression, signal transduction (abst) EGF, aminopeptidase N, 5'-NU (abst) ET-1 induces cyclooxygenase-Il extracellular ATP, UTP, membrane voltage (abst) Fey receptor III (CD16) (abst) FGF, PDGF, IL-1/3 induced NOS (abst) filtering surface area, ACEi (abst) 5' region enhancer, 72 kD collagenase IV (abst) gentamicin, ET, NO (abst) gentamicin, PAF growth abnormalities, GS heparan sulfate proteoglycan perlecan (abst)

991

692 688 669 692 829 682 991 671

989 25 .

.

.

671

673 984 669 699 53 700 670 695

676 974 685 1346 106 690

1891

Subject Index: VoL 47

heparan sulfate proteoglycans, Ang II (abst) high glucose, GF gene expression (abst) ICAM-1, /31 integrin, GN (abst) ICAM-1, /31 integrin, high glucose (abst) ICAM-1, MNC, cytokines, IgA nephropathy (abst)

IL-i, cyclooxygenases, prostacyclin, TxA2 (abst)

701

693 352 352 352 686 687 992

IL-i induces IL-8, IL-6, cAMP (abst) IL-1/3, NOS, dexamethasone, cAMP (abst) 365 integrins, IgA modulatory role (abst) 689 intraglomerular transplantation (abst) lack of insulin effect, SHR 891 690 LDL, proteoglycan production (abst) 351 lipocortin-1 inhibits proliferation (abst) 351 lovastatin, PDGF (abst) 1000 mitogenic effect, extracellular ATP (abst) 473 Na/myo-inositol cotransport 990 NOS expression, IL-1/3, MC (abst) proliferation, dinucleotides, phospholipase C, AP4A 1007 receptors (abst) 811 puromycin aminonucleoside, ROS 1258 receptor-mediated binding, nucleosomes 500 regulation of iNOS expression 688 serotonin, phospholipase D (abst) 364 smooth muscle a-actin, IgA nephropathy (abst) 666 somatostatin, intracellular cGMP synthesis (abst) 673 TGF-/3 production, high glucose (abst) 687 tyrosine phosphorylation, PDGF (abst) 660 U-937 monocyte adhesion (abst) 62 Mesangial proliferative nephritis, INF-y Mesothelial cells 1274 endocytosis, transcytosis of albumin gold lactate-buffered CAPD fluids 282 997 peritoneal fibrinolytic system, CAPD (abst) Metabolic acidosis 354 anion gap patterns, HD (abst) chronic renal failure (abst) 355 355 hyperkalemia, NaHCO3 insulin in glucose (abst) 1790 osteoblastic intracellular pH and Ca 691 prolonged, chronic renal injury (abst) 979, 980 Metabolic risk factors, post-transplant (abst) 207 Methicillin-resistant S. aureus, GN Methylmalonic acid serum concentration, uremia (abst)... 964 Methyiprenisolone pulse therapy, steroid-resistant NS 348 (abst) Microalbuminuria 962 antihypertensive therapy (abst) 962 elderly, antihypertensive therapy (abst) 1223 endothelial dysfunction, IDDM (abst) 674 glomerular changes, DM (abst) 1224 high serum prorenin, IDDM (abst) non-diabetic hypertensives, other concomitant diseases 962 (abst) non-diabetic hypertensives, with/without end-organ 962 injury (abst) 164 Microcytosis, aluminum-induced Microform of PAN, Wegener's granulomatosis (abst). . . . 1000 Micropuncture 1023 lithium handling 667 Na reabsorption, Henle's loop (abst) 682 tubular site of action, furosemide (abst) 368 Microscopic polyarteritis, anti-MPO antibodies (abst) Minimal change disease (MCD) 347 Ciq nephropathy (abst) 346 children (abst) 1218 proteinuria pathogenesis (abst)

Mitochondrial myopathy, encephalopathy, lactic acidosis, stroke-like episodes (MELAS), renal failure (abst) . . . 1219 Monoclonal antibodies (MAB) anti-APA, PT APA redistribution (abst) 1221 1222 anti-lymphocyte, fail to prevent rejection (abst) TN2O, interstitial renal fibrosis (abst) 673 Monoclonal gammopathy, immunotactoid-like glomerulopathy, liver/bone marrow fibrillary deposits 998 (abst) Monocyte chemoattractant protein-i (MCP-1) 691 GS, PAN, TGF-/3 (abst) 692 interstitial nephrosclerosis, ICAM-1 (abst) 705 PTEC production (abst) Monocytes, U-937 cell line, MC adhesion (abst) 660 Monokines in HD patients 559 Mononuclear cells (MNC) 352 ICAM-1, MC, cytokines, IgA nephropathy (abst) 1158 LPS-induced IL-1/3 production/secretion 972 Moxonidine, urinary Na, renal hemodynamics (abst) 122 MRL-lpr mice, biphasic TNF-a Muscarinic agonists, phoshoinositide metabolism, PT 665 (abst) Muscarinic receptors, forearm vascular bed, hypertension 705 (abst) .

N N-acetyl-/3D-glucosaminidase, contrast media nephrotoxicity (abst) Nat-coupled uptake, BBM fluidity, cisplatin

342 1048

Na excretion

magnesium, renin, relative heart weight (abst) urinary, moxonidine, renal hemodynamics (abst)

995 972

ADH, Ang II, diadenosines, CCD (abst) antiporter (NHE-1 isoform) in VSMC isoforms, RT-PCR detection, outer medulla (abst) macula densa cells mammalian gene, structure/function (abst)

999 78 674 746 674

Na/H exchange

Na homeostasis, post-HLA identical transplant (abst) ...

708

Na/K-ATPase calcium channel blockers, acute ischemic RF (abst) . . . . 345 680 exogenous 0-subunit expression, EC (abst) 680 gene transcription, glucocorticoids (abst) 663 lipid peroxidation, PT cells (abst) 678 neuropeptide Y, proinsulin C-peptide (abst) 675 phosphorylation, protein kinases (abst) 696 PKC phosphorylation, E1-E2 (abst) 659 pump recruitment, cell volume, CCD (abst) Na/Li red cell countertransport, IgA nephropathy (abst) . . 366 473 Na/myo-inositol cotransport, MC Na/P-cotransport system 675 acute up-regulation, proximal tubular (abst) baculovirus-infected insect cells (abst) 662 662 electrophysiology, xenopus oocytes (abst) 663 molecular aspects in flounder (abst) 662 mRNA/protein level (abst) 663 sensitivity differences, PT (abst)

Na reabsorption

barium effect (abst) micropuncture/clearance measurement (abst) proximal tubular, acute K loading (abst) taurine dependent, furosemide (abst) Na sensitivity, vascular compliance, hypertension

Na transport

adenosine, A1 receptor, [Ca2]

663

667 667 997 169

1576

1892

in ATL extracellular ATP, PKC (abst) sulfate, phosphate, mRNA expression (abst) sulfate, phosphate, xenopus oocytes (abst) Na:2C1:K transport, macula densa cells

NaHCO3

Subject Index: Vol. 47

789 705

662 662 752

680 cotransport, acetazolamide action (abst) 1669 cotransport, glucocorticoids 968 cotransport, HCO3 conductance (abst) hyperkalemia, metabolic acidosis, insulin in glucose 355 (abst) Natriuresis ANP, albuminuria, glomerular permeability, NS (abst).. 993 682 arginine vasopressin (abst) ICy immunoneutralization, ANP, renal function (abst) . 682 666 oxytocin, hypertonic NaC1 (abst) 682 post-prandial, peptide tyrosine (abst) 1217 renin-inhibition, EH (abst) 342 Neonates, indomethacin, renal hemodynamics (abst) 353 Neopterins, serum/urinaly, CRF (abst) Nephrectomy, unilateral 442 female analbuminemic rats, hyperlipidemia, GS 1008 plasma/urine ET-1 (abst) 982 RA occlusion, hypertension (abst) Nephritis. See also Glomerulonephritis 344 acute bacterial (abst) 758 bull terrier hereditary 349 Henoch-SchOnlein purpura (abst) 1604 Heymann, complement C6 689 Heymann, gp330 eDNA coding (abst) 432 Heymann, receptor-associated protein 692 Heymann, renal injury, NOS inhibition (abst) 986 interstitial, megalocytic, E. coli bacteremia (abst) 481 lupus, ETA receptor antagonist 701 lupus, heparan sulfate staining, GBM (abst) 148 lupus, PAl-i expression 1168 lupus, TXA2 synthase inhibition 62 mesangial proliferative, INF-y 660 nephrotoxic, chemokines, leukocyte influx (abst) 454 nephrotoxic serum, anti-MPO antibodies Nephrocalcinosis 1419 familial hypomagnesemia, hypercalciuria 995 medullary, sonography, adults (abst) Nephronophthisis 1008 osseus malformations (abst) 662 retinitis pigmentosa (abst) Nephrons 680 distal, NaC1 transport, DNA synthesis (abst) 49:S-51 experimental models of reduction 536 Mn-SOD mRNA localization 707 number, pre-transplantation (abst) 679 organic osmolytes along (abst) 1078 single nephron albuminuria 1217 single nephron albuminuria (abst) Nephropathy. See also Diabetic nephropathy; IgA nephropathy analgesic, post-transplant, urothelial carcinoma (abst). . . 984 689 experimental, heparin dosages/targets (abst) 349 membranous, clinical review (abst) 677 membranous, FGF, podocytes (abst) 225 membranous, HBV, INFa 1218 membranous, idiopathic, urinary 2-M (abst) 1130 membranous, progressive, cyclosporine 1108 reflux, children, glomerular morphometry rheumatoid arthritis (abst) 350

sulphated glycosaminoglycans, proteinuria (abst) Nephrosis adriamycin, antiproteinuria, ACEi (abst) PAN, 43 dDal glycoprotein, in GEC (abst) Nephrotic dyslipidemia, LDL metabolism Nephrotic syndrome adult, biopsy analysis (abst) adults, fibrinolysis, renal vein thrombosis (abst) ANP, natriuresis, albuminuria, glomerular permeability (abst) bumetanide (abst) Clq nephropathy (abst) children, sonography (abst) children, steroid-resistant, MP pulse therapy (abst) children, steroid-responsive children, steroids, bone metabolism (abst) children, steroids, CsA, INF-y, IgEr-Il (abst) children, urinary f32-M, proteinuria (abst) hypertriglyceridemia idiopathic, uremia (abst) Nephrotoxic nephritis anti-MPO antibodies chemokines, leukocyte influx (abst) Nephrotoxicity contrast media, ionic/nonionic contrast media, N-acetyl-D-glucosaminidase (abst) . . . . CsA, arginine, modulated by NO CsA, lipid peroxidation, vitamin E CsA, membranous nephropathy cytoprotection, silibinin, SOD (abst) Russell's viper venom Netilmicin, PAN membrane, HD (abst) Neuraminidase, kidney cellular infiltration Neuropeptide Y, proinsulin C-peptide, Na/K-ATPase (abst) Neutral endopeptidase TGF-f3, EGF, VSMC (abst) urinary, and salt loading Neutral horseradish peroxidase, charge selectivity Neutrophils apoptosis, eDNA cell transfection, CD36 (abst) cellular infiltration, neuraminidase elastase, cathepsin G, CD43 shedding (abst) lipoxin synthesis, GN pathogenesis, experimental vasculitis (abst) NF-kB DNA-binding, commercial dialysate NH4C1, cellular hypertrophy, lysosomal cysteine

proteinases (abst) NHE-1 isoform (Na/H antiporter), VSMC Nicardipine, compared to nifedipine (abst) Nifedipine compared, enalapril, BP, ET (abst) RAS effects, compared to nicardipine (abst) RAS effects, erythropoietin (abst) Nitrate in stable CAPD and peritonitis (abst) Nitrendipine, urinary enzymes, proteinuria, contrast media (abst) Nitric oxide (NO) blockade, tubuloglomerular feedback (abst) blockade induces FSGS (abst) endothelial cells, CsA (abst) ET, gentamicin activation, MC (abst) ET-1, human renal function (abst) ET-1, ischemia/reperfusion injury (abst) glomerular blood flow control (abst)

1224 1223 689 579 345 1483

993 354 347 346 348 1392 347 346 346 566 348 454 660 254 342

1507 927 1130 971 518 982 88

678 665 855 1630 671 88

672 1295 672 1537 1003 78 683 1216 683 683 1217

369 695

696 670 685

707 677 676

Subject Index: Vol. 47

695 hemodynamic flow, vascular EC (abst) 353 hemorrhagic fever with renal syndrome (abst) 1515 L-arginine, captopril, CRF 1507 modulates CsA toxicity, arginine 365 production during dialysis (abst) 366 renal autoregulation, intravital microscopy (abst) Nitric oxide synthase (NOS) 363 blockade, removal during HD (abst) 353 central/peripheral pressor effects (abst) 694 consequences of regulation (abst) 992 dexamethasone, IL-113, cAMP, MC (abst) 353 Ginseng Saponin effects (abst) 692 Heymann nephritis (abst) 685 IGF-1 aminoguanidine (abst) 500 inducible, regulation in MC 967 localization, mammalian kidneys (abst) 990 NO expression, IL-1j3, MC (abst) RAS distribution, juxtaglomerular apparatus (abst). 670, 964 1252 reabsorption of NLA, TGF responses Non-insulin dependent diabetes mellitus (NIDDDM) 1781 DN type II 1697 hypertension, renal function, black subjects Nonimmunologic late renal graft loss, Nephrology 1470 Forum 352 Norepinephrine, RA pressure, renal urokinase (abst) 658 Nuclear pore complexes, MDCK cells (abst) Nucleosomes bind to glomerular MC 1258 Nucleotides 700 extracellular, Ca, cortical TAL, Henle's loop (abst) 699 extracellular, renal handling (abst) 1500 extracellular, renal tubular transport Nutritional assessment 1148 amino acid-based dialysate, CAPD CAPD and HD compared (abst) 358, 359 359 rhGH, malnourished adults, CAPD (abst) 358 urea kinetic modeling, CAPD (abst) urea kinetic modeling, one-compartment, HD (abst). . . . 970

0 Obstruction

proximal tubular cytoresistance unilateral, nephropathy, Ang II Ochratoxin A, kidney and renal cell lines (abst) OKT3 biphasic gratiulocytopenia, after one dose (abst) resistant rejection, FK506 (abst) Oligonucleotides genes, organ development (abst) phosphorothioate, renal transport Oncogenesis, targeted, renal cell lines One-compartment (blood) UKM, HD (abst) One-line dialysate HD method (abst) 1-desamino-8-D-arginine vasopressin (DDAVP), EFI (abst) 1,25-dihydroxycholecalciferol, ICAM-1, EC (abst) 1,25(OH)2D3 receptor level, uremia (abst) Ontogeny Ang2 receptor mRNA angiotensin receptors epithelial polarity, ureteric bud cell culture (abst) Opiate intoxication, extracorporeal detoxification (abst). . Organic cations, renal transport Organic ion excretion in kidney (abst) Organic osmolytes along rodent nephrons (abst)

628 1285 965

1218 975 693 1462 388 970 970 706 968 665 1095

140 978 1007

1647 681

679

1893

664 chronic diuresis, urine concentration (abst) 996 effiux, CD cells, G-proteins (abst) ischemia, free amino acids, cortex/outer medulla (abst) . 991 in mesangial cells 473 664 salt adaptation (abst) 678 Ornithine metabolism, experimental GN (abst) 678 Osmolality, extracellular and taurine effiux (abst) 1008 Osseus malformations, nephronophthisis (abst) 1790 Osteoblastic intracellular pH and Ca, acidosis Osteopathy 984 femoral head necrosis, post-transplant (abst) 1000 low turnover, long-term HD (abst) 1585 Osteopontin expression, kidney Ouabain-like factor, intracellular Ca, CD cells (abst) .. . . 1006 Oxidant-induced PT cell injury, Ca (abst) 343 1101 Oxidative phosphorylation diseases, aminoaciduria Oxygen dependent expression, EPO mRNA, kidneys 694 (abst) 995 Oxygen radicals as biocompatibility markers (abst) 666 Oxytocin, natriuresis, hypertonic NaCl (abst)

P P-cresol role, phagocyte function Pancreas/kidney transplant, UTI, DM, NaHCO3 loss, theophyllin (abst) Pantoprazole pharmacokinetics, HD (abst) Para-aminohippurate (PAH) excretion, without urine examination (abst) secretion, a-ketoglutarate (abst) Paraquat intoxication, hemoperfusion (abst) Parathyroid hormone (PTH) autoregulation of secretion (abst) bone disease, pre-dialysis/dialysis bone disease, uremia, diabetes lung and right ventricle, CRF PKC, adenylate cyclase desensitization PTH-related protein receptor, Ca, CRF receptor down-regulation, uremia Parathyroidectomy anaphylaxis, heparin, thrombocytopenia (abst) PTH receptor down-regulation, uremia serum phosphate concentration, HD (abst) Pediatric donor kidneys, age-matching (abst) Peptide tyrosine, post-prandial natriuresis (abst) Peripheral blood T-lymphocyte subsets, immunosuppression (abst) T-lymphocyte subsets, renal cell carcinoma (abst) Peripheral vein, measurement vascular access recirculation (abst) Peritoneal dialysis AGE products in dialysis fluid albumin-based solutions (abst) assessing individual capacity exit-site infections, local antibiotics (abst) exit-site/sinus-tract infections, sulcus fluid flow rate (abst) peritoneal macrophages characterized (abst) prescription, "clearance peak" model (abst) sieving coefficient, small solutes (abst) tidal, prescription, PET (abst) Peritoneal equilibration test (PET) compared, peritoneal permeability analysis (abst) diabetes, peritonitis tidal peritoneal dialysis (abst) Peritoneal lymphatic pathways, albumin, RBC transport (abst)

510 1001 984

970 663 359 363 1434 1746 158 38 1182 1797 1003 1797 1000 996 682

361 345 356 1768 358 1187 982

994 1481 371 358 369 1217 1760

369 684

1894

Peritoneal mesothelium endocytosis/transcytosis, albumin gold SITS and DIDS, anionic transport (abst) Peritonitis effect on PET with diabetes nitrate levels, CAPD (abst) peritoneal fibrosis, CAPD (abst) Permcath complications, changing pattern (abst) PGF1, TxB2, cyclosporin, post-transplant (abst)

pH acidosis, trade-offs in, Nephrology Forum CAPD patients cell volume, acidic cellular compartments (abst) cytosolic, K conductance, PT (abst) intracellular, lipid peroxidation, PT cells (abst) K response, acute respiratory alkalosis metabolic acidosis, anion gap patterns, HD (abst) metabolic acidosis, CRF (abst) osteoblastic intracellular, Ca, acidosis papillary gradient, CD urine, vasa recta, diuresis

Subject Index: Vol. 47

1274 683 1760 1217 358 977 360 1205 269 681 965 681 217 354 355 1790

681, 987 (abst) 333 transport, inner medullary CD, Nephrology Forum 624 urinary parameters, chronic renal acidosis 510 Phagocyte function and p-cresol Pharmacokinetics 982 anti-infective therapies, RI (abst) 354 bumetanide (abst) 988 lopentol, RI (abst) 984 pantoprazole, HD (abst) 869 rHuIGF-1, dialysis Phoshoinositide metabolism, muscarinic agonists, PT 665 (abst) Phosphate serum concentration, parathyroidectomy, HD 1000 (abst) 664 Phosphoenolpyruvate carboxykinase (PEPCK) (abst) 687 Phosphoinositidase C activation, glomeruli (abst) Phospholipase C 1007 dinucleotides, AP4A receptors, MC (abst) 669 extracellular ATP, c-fos, P2u-receptors, MC (abst) 688 Phospholipase D, serotonin, MC (abst) 1087 Phospholipid hydrolysis, plasmalogen, PT hypoxia Phosphorothioate oligonucleotides 1462 renal transport Phosphorylation aminoaciduria, OXPHOS defects 1101 696 PKC, E1-E2 transition, Na/K-ATPase (abst) 675 protein kinase sites, Na/K-ATPase (abst) Plasma exchange, amyloidosis, cytotoxic drugs (abst) . . . . 1485 686 Plasma membranes, inositol lipid signalling (abst) 1087 Plasmalogen phospholipid hydrolysis, hypoxic PT Plasminogen activators 148 inhibitor-i expression, lupus nephritis 1039 plasmin, MMP-2 cascade, ECM degradation 49:S-12 remodel ECM, metalloproteinases Platelet activating factor (PAF) 676 endotoxin, glomerular resistance (abst) 1346 gentamicin, mesangial cells Platelet-derived growth factor (PDGF) 670 distribution, PKC-a/, VSMC (abst) 695 FGF, IL-ip, NOS, MC (abst) 131 modulated by Ang II 660 tyrosine kinases, angiogenesis (abst) 687 tyrosine phosphorylation, MC (abst) Platelets 1295 adhesion, lipoxin synthesis, GN

anti-idiotypic antibody detection, anti-HLA-I (abst) . . . 1483 PMN functions, uremia, immunoglobulin light chains 969 (abst) Podocytes 689 adhesive phenotype, FSGS (abst) 986 injury, development of GS (abst) 677 injury, FGF, membranous nephropathy (abst) 1078 single nephron albuminuria 1217 single nephron albuminuria (abst) 689 undergo mitosis, not cell division, FGF (abst) Polyacrylonitrile (PAN) membrane, drug kinetics, HD 982 (abst) 1485 Polyamide membrane HD, lipid profiles (abst) 972 Polyamines, RBC/plasma, HD (abst) Polyarteritis nodosa, Wegener's granulomatosis (abst) . . . 1000 Polyclonal anti-lymphocyte antibodies, rejection (abst)... 1222 Polycystic kidney disease (PKD) 973 chloride/protein intake, hypertension (abst) 715 EC growth, abnormal regulation 720 EC transport, abnormal EGF receptor, CPK mouse kidney 490 728, 729 genetic study 996 HLA-DRB1, PKD-i gene analysis, adults (abst) molecular basis 715—732 new mouse mutant model 552 966 Polyethylene coating, cellulose membrane (abst) Polymorphonuclear leukocytes, [Ca2I carbohydrate 1741 metabolism, verapamil Polysulphone dialyzers 966 compared, AMBIO dialyzer (abst) 638 heat disinfection 573 reuse and protein loss Polytetrafluoroethylene (PTFE) grafts, AV fistulae, 1484 seroma formation (abst) Polyunsaturated free fatty acids, antidiuresis, vasopressin 687 (abst) Post-prandial natriuresis, peptide tyrosine, renal function 682 (abst) 262 Post-prostatectomy syndrome 1004 Pre-eclampsia, ARF (abst) 347 Prednisolone, NS, children, bone metabolism (abst) Pregnancy 369 post-transplant (abst) 1004 pre-eclampsia, ARF (abst) 1004 successful in CAPD patient (abst) 1004 Tamm-Horsfall protein, urinary excretion (abst) 327 Prenatal diagnosis of Alport syndrome 981 Pressimmun therapy, acute rejection (abst) 1482 Primary hyperoxaluria type I (abst) Primary hypertension, ADPKD renal prognosis (abst) . . . 1002 Primary vasculitis renal, leukocyte infiltration, ICAM-1, VCAM-1 (abst) .. 363 systemic, MHC class II alleles 294 Proliferative glomerulonephritis 1121 anti-MPO, ischemia/reperfusion injury 688 apoptosis, mesangial cell (abst) 114 apoptosis in repair process 988 Propafenone intoxication, hemoperfusion (abst) Prorenin plasma, CsA increases in bone marrow (abst) 966 1224 serum, microalbuminuria, IDDM (abst) 686 Prostacyclin synthase, IL-i, MC (abst) Prostaglandins bone disease, f32-M, IL-1f3

endothelin effects

587 795

Subject Index: Vol. 47

996 fibrinolysis, ET-1, ARF (abst) 668 NaCI delivery, medullary interstitium (abst) 282 peritoneal mesothelial cell synthesis 973 production, ET, dopamine (abst) 1007 proteinuria, glomerular permeability, GN (abst) renal baroreceptor mechanism, renin secretion (abst). . . 985 Protectin, urinary, complement SC5b-9, cytokines, MGN. 1403 Protein, dietary 973 intake, hypertension, PKD (abst) 353 renal effects, early CRF (abst) 7 urine concentration in health and CRF Protein-A immunoadsorption, life-threatening SLE (abst) . 967 Protein kinase C 670 a/n, VSMC, PDGF (abst) 696 Ang II effect, PT (abst) 696 E1-E2 transition, Na/K-ATPase (abst) 705 extracellular ATP, Na transport (abst) 1057 isoforms, high glucose, VSMC isoforms in renal tissue 766 38 PTH, adenylate cyclase desensitization 705 verocytotoxin receptor, endothelial cells (abst) Protein kinases 688 cAMP-mediated glomerular function (abst) 675 Na/K-ATPase phosphorylation (abst) TGF-131, proteinase activity, LLC-PK1 cells (abst) . . . . 1003 573 Protein losses with reused dialyzers Proteinase 3, ANCA inhibition, Wegener's 1528 granulomatosis Proteins 965 BBM as markers, PT injury (abst) 659 GP280/GP330 expression, endocytosis (abst) 70 granzyme, expression in rejection 432 receptor-associated 39/45 kD, Heymann nephritis 658 sorting, polarized epithelial surface (abst) 1009 synthesis, glomerular proteolysis, GS (abst) Proteinuria 1223, 1224 anti-proteinuric effect, ACEi (abst) 1008 CsA-associated arteriopathy, albuminuria (abst) 677 FGF, podocytes, membranous nephropathy (abst) 706 glomerular apo deposits, analbuminemia (abst) 1007 L-arginine, GN, hypertension (abst) 1224 nephropathy, sulphated glycosaminoglycans (abst) 1007 PGE1, glomerular permeability, GN (abst) 1546 protein-overload, interstitial renal fibrosis 346 SDS-PAGE method, children, NS (abst) 442 uninephrectomized female analbuminemic rats Proteoglycans 698 collecting tubule principal cells, SV4O (abst) 690 MC production, LDL (abst) 690 perlecan, modulates MC (abst) 690 synthesized, compared glycosaminoglycans (abst) 659 Proteolysis, angiogenesis, cytokines (abst) Proto-oncogenes 718 cell proliferation 782 diabetic renal hypertrophy Proximal tubules 675 acute up-regulation, Na/P-cotransport 696 Ang II effect, PKC (abst) 343 Ca, oxidant-induced cell injury (abst) 702 calcium channel blockers, anoxic PT injury (abst) 1000 catalytic activity, cathepsin S (abst) 680 cell culture medium effect (abst) 1048 cisplatin, Na-coupled uptake, BBM fluidity 1669 glucocorticoids, NaHCO3 cotransporter 659 GP280/GP330 expression, endocytosis (abst)

gp330, endocytosis of aprotinin (abst) HSP7O mRNA, ischemic injury (abst)

IL-8, INF-y, IL-1, TNF-a (abst) injury, BBM protein markers (abst)

1895 679 986 704 965 965 697 681 663 705 395

K conductance, cytosolic pH regulation (abst) K transport, fluid reabsorption (abst) lipid peroxidation, intracellular pH (abst) lipid peroxidation, Na/K-ATPase (abst) MCP-1, IL-la, TNF-a (abst) mercury toxicity monoclonal anti-APA antibodies, APA redistribution 1221 (abst) muscarinic agonists, phoshoinositide metabolism (abst). 665 667 Na, K reabsorption with K loading (abst) 663 Na/Pt uptake sensitivity (abst) 628 obstruction, cytoresistance, hypoxic injury 1087 plasmalogen phospholipid hydrolysis, hypoxia 677 upregulation, IL-2rcE (abst) 704 Psoriasis, RAS, renal hemodynamics, CsA (abst) 365 Pulmonary hemorrhage, ANCA-positive vasculitis (abst) 158 Pulmonary hypertension/calcification, PTH, CRF 1000 Purine nucleosides, ATP, mitogenic effect, MC (abst). 699 Purine nucleotide cycle, kidney cortex/medulla (abst) Puromycin aminonucleoside (PAN) 691 US severity, MCP-1, TGF-/3 (abst) 811 mesangial cells, ROS 689 nephrosis, 43 dDal glycoprotein, GEC (abst) Pyelonephritis 362 acute, RF, post-transplant (abst) 973 E. coli, uropathogenic virulence (abst) 964 Pyelons, acutely dilated, measurement by AP (abst) 344 Pyeloplasty, children with UUO (abst)

R Racial differences hypertension, allograft survival hypertension, NIDDM, renal function rBAT and heavy metal intoxication Reactive oxygen species, mesangial cells and PAN Recombinant human erythropoietin (rHuEPO) LH kinetics/biopotency, men, HD (abst) stimulates angiogenesis Recombinant human growth hormone, malnourished adults, CAPD (abst) Recombinant human IGF-1 impaired metabolic response, dialysis patients pharmacokinetics, dialysis patients Recombinant IL-2, uremia, HBV vaccine non-responders (abst) Red blood cells, polyarnines, HD (abst)

1136 1697 1677 811 1004 740

359 876 869 1483 972

Reflux nephropathy, children, glomerular morphometry.. 1108 672 Refractory systemic vasculitis, thalidomide (abst) Rejection. See also Immunosuppression 981 acute, Pressiummun therapy (abst) 70 acute allograft, granzyme expression 703 biopsy findings (abst) 361 chronic, IL-i, TGF-j3 (abst) 1491 chronic transplant loss ICAM-1 and VCAM-1 1383 997 influence of age (abst) 371 local transcription, complement C3 (abst) 708 monoclonal anti-IL-2R antibody, prevention monoclonal/polyclonal anti-lymphocyte antibodies 1222 (abst) 1005 non-immunologic factors (abst)

1896

Subject Index: l/ol. 47

975 OKT3 resistant, FK506 salvage (abst) 333 Renal acid-base transport, Nephrology Forum Renal ammoniagenesis, ASA, salicylic/salicyluric acids 664 (abst) Renal artery endothelium-dependent dilation, oxidized Lp(a), HDL 684 (abst) 982 occlusion, hypertension, unilateral kidney (abst) 352 pressure, urokinase, norepinephrine (abst) 1219 stenosis, fibromuscular dysplasia (abst) 978 stenosis, renin mRNAlsecretion, BP (abst) 985 Renal baroreceptor mechanism, prostaglandins (abst) .. Renal biopsy 370 adhesion molecule distribution (abst) 345 adult nephrotic syndrome (abst) 703 allograft rejection (abst) 347 Clq nephropathy (abst) 998 CsA-associated arteriopathy (abst) 346 glomerular disease (abst) 1222 Wegener's granulomatosis (abst) Renal blood flow 685 flow dependence, pressure diuresis (abst) 1220 hippurate clearance (abst) 345 Renal cell carcinoma, peripheral T-celI subsets (abst) Renal cell lines 322 adenovirus-mediated gene transfer 965 ochratoxin A distribution (abst) 388 targeted oncogenesis Renal development 661 embryonic ureteric bud cell expression (abst) 1597 GATA-3 expression 661 induced nephron deficit (abst) 679 mitochondrial ATP-synthase (abst) 659 normal human, MMPs and TIMP, ARPKD (abst) 986 novel gene products identified (abst) 661 regulatory gene expression (abst) 678 sorbitol pathway, perinatal rats (abst) 680 transcription, Na/K-ATPase gene (abst) 661 transcription factor Kid-i (abst) 669 transcriptional modulation, kidney genes (abst) 693 transcriptional regulation (abst) vasopressin mechanism of action (abst) 679 661 Wilm's tumor protein (abst) Renal disease 1319 ACEi, endothelin prevent RF/death 1811 ancient Babylonia 49:S-44 progression, chemokine role 1327 stretavidin, targeted therapy Renal failure. See also Acute renal failure; Chronic renal failure 1219 in MELAS (abst) 362 pyelonephritis, post-transplant (abst) 702 Rf-1 gene identification (abst) Renal function 975 Ang (1-7) response (abst) cAMP as second messenger, organic anion transport 977 (abst) 795 endothelin effects 666 ET-1 and L-arginine (abst) 668 5HTia receptor agonist, BP (abst) 971 heavy metal exposure (abst) 1697 hypertension, black NIDDM subjects 682 ICV immunoneutralization of ANP (abst) 707 NO stimulation, ET-1, humans (abst) 682 peptide tyrosine, post-prandial natriuresis (abst) .

.

post-lung transplant (abst) post-sino-carotid denervation, ANP (abst) sino-carotid denervation, ANP, endocrine function (abst) vasopressin, molecular level response (abst) Renal functional reserve impairment, grafts (abst) Renal glutaminase, protein deprivation (abst) Renal glutamine metabolism Renal growth hormone, IGF-1, ARF Renal hemodynamics afferent arteriolar response, Tolrestat (abst) ANP, acute volemic stress (abst) anti-thymocyte-antibody, complement (abst) antiproteinuric effect, ACEi (abst) dopa i.v., normotensive ADPKD (abst) endothelin effects indomethacin in neonates (abst) L-arginine, proteinuria, GN, hypertension (abst) PGE1, proteinuria, GN (abst) RAS, psoriasis, CsA (abst) RPP reduction, Ang II, renal nerve (abst) terminal respiratory failure (abst) urinary Na excretion, moxonidine (abst) vascular endothelial growth factor (abst) Renal infarction, terminal complement cascade Renal injury. See Injury, renal Renal insufficiency aluminum toxicity (abst) anti-infective therapy (abst) chronic, K permeability disorders (abst) guanidino compound metabolism iodine monitoring, contrast medium (abst) magnesium transport, cell membranes (abst)

704 668 683 660 974 664 96 1658

1221 686 686 1224 1218 795 342 1007 1007 704

1220 1220 972 983 918

983

982 974 464 983 983 988

pharmacokinetics, lopentol, RI (abst) Renal osteodystrophy and acidosis, Nephrology Forum . . 1816 Renal papillary pH gradient, CD urine, vasa recta, 681, 987 diuresis (abst) 1220 Renal perfusion pressure, Ang II, renal nerve (abst) 411 Renal regeneration, clusterin expression, apoptosis Renal replacement therapy (RRT) 1003 Eastern Germany (1993) vs. GDR (1989) (abst) 366 risk factors with DM (abst) 666 Renal reserve measurement, urinary flow rate (abst) 661 Renal transcription factor Kid-i (abst) Renal vasculature 684 cortical/juxtamedullary, ET (abst) 1217 renin-inhibition, natriuresis, EH (abst) 676 vasomotor response propagation (abst) 1483 Renal vein thrombosis, adult NS, fibrinolysis (abst) Renin-angiotensin-aldosterone system 683 nifedipine, EPO (abst) 683 nifedipine, nicardipine compared (abst) Renin-angiotensin system (RAS) 703 cardiac interstitial fluid (abst) 670, 964 NOS, juxtaglomerular distribution (abst) 669 oncogene expression, Ca oscillations (abst) 704 renal hemodynamics, psoriasis, CsA (abst) 703 renal/systemic response, EH (abst) 354 suppressed, anemia, CRF (abst) Renin gene expression 1266 cellular regulation 685 OM 2-kidney, 1-clip rats (abst) renal baroreceptor mechanism, prostaglandins (abst) . . . 985 978 unilateral RAS, BP (abst)

Subject Indcc: Vol. 47

Renin secretion 675 juxtaglomerular cells, chloride (abst) 669, 985 juxtaglomerular cells, ET (abst) 45 juxtaglomerular cells, LDL, Lp(a) 995 magnesium, Na, relative heart weight (abst) 1217 natriuresis inhibition, EH (abst) 967 pressure-dependent, ADPKD (abst) 675 pressure-dependent, calcium (abst) Reperfusion injury. See Injury, renal Respiratory acidosis, osteoblastic intracellular pH, Ca . . . 1790 1220 Respiratory failure, renal hemodynamics (abst) Rhabdomyolysis case analysis (abst) lipid-lowering agents, post-transplant (abst)

Rheumatoid arthritis, nephropathy (abst) Richet, Professor Gabriel Right ventricular hypertrophy, PTH, CRF Russell's viper venom, nephrotoxicity

343

362 350 49:S-2 158

518

S S-adenosylhomocysteine, erythrocytes, uremia

Salicylic/salicyluric acids, renal ammoniagenesis (abst) .

247 664

Salt 664 adaptation, organic osmolytes (abst) 681 adenosine, TAL, Henle's loop (abst) 668 cortico-papillary gradient, vasopressin V2r (abst) 668 delivery to medullary interstitium (abst) 855 loading, urinary neutral endopeptidase Salt, dietary 686 adenosine-hypersensitivity, glomeruli (abst) 992 albuminuria, EH (abst) 978 ambulatory BP monitoring, EH (abst) 366 hyperfiltration, EH (abst) 899 restriction, calciuria, K-deprivation 169 sensitivity and vascular compliance Salt transport 680 distal nephron segments, DNA synthesis (abst) 1615 modulation, DNA synthesis Sandimmun-Neoral conversion (abst) 990 1403 SC5b-9, urinary, CD59, cytokines, MGN Second messenger control, renin mRNA, juxtaglomerular 669 cells (abst) Secondary hyperparathyroidism, bone disease, uremia, 1746 DM Secondary membranoproliferative GN, Nephrology Forum 643 662 Senior-Loken syndrome (abst)

Seroma formation, PTFE grafts as AV fistulae (abst).... 1484 688 Serotonin activates phospholipase D, MC (abst) 72 kD collagenase-IV gene, MC enhancer (abst) 974 Silibinin 673 cytoprotection, fibronectin turnover (abst) 971 cytoprotection, nephrotoxicity, SOD (abst) 698 Simian virus 40, proteoglycans, CD (abst) 1078 Single nephron albuminuria 1217 Single nephron albuminuria (abst) Sino-carotid denervation 683 ANP, renal/endocrine function (abst) 668 ANP, renal function (abst) Sinus-tract infections, sulcus fluid flow rate, PD (abst) . . . . 994 364 Smooth muscle a-actin (nSMA), IgAN, MC (abst) 518 Snake venom nephrotoxicity 721 Solute transport mechanisms, pulmonary epithelial 666 Somatostatin, cGMP synthesis, MC (abst) Sonography 346 children with NS (abst)

EH, renal resistance index, age (abst) medullaty nephrocalcinosis, adults (abst) Sorbitol pathway, development (abst) Staghorn calculi, ESWL monotherapy (abst)

1897 986 995 678 345

Staphylococcus aureus 207 methicillin-resistant, GN 994 prophylaxis, CRIs (abst) Steroids 347 NS, children, bone metabolism (abst) 346 NS, children, CsA, INF-y, IgE-Ril (abst) 1392 NS, children, favorable course 348 NS, children MP pulse therapy (abst) Stilbene derivatives (SITS and DIDS), peritoneal 683 transport (abst) Stretavidin, renal accumulation 1327 Sulcus fluid flow rate, PD exit-site infection (abst) 994 982 Sulmycin Implant, PD exit-site infection (abst) Suiphated glycosaminoglycans, proteinuria, nephropathy 1224 (abst) Superoxide dismutase (SOD) 971 cytoprotection, nephrotoxicity, silibinin (abst) 536 gene activation, nephron locus SV4O T-oncogene, 92/72-Wa collagenase-IV, CD (abst) .. 665 Systemic lupus erythematosus (SLE) 369 antiphospholipid antibodies (abst) 989 circulating adhesion molecules (abst) 963 histology/clinical course (abst) 1258 nucleosome binding, glomerular MC 148 PAl-i, lupus nephritis 967 protein-A immunoadsorption (abst) 1484 vascular access clotting (abst)

T T-cell hybridoma, HgC12-induced, cytokines (abst) T-cell subsets pre-transpiant immunosuppression (abst) renal cell carcinoma (abst)

694 361

345

T-cells

Goodpasture's syndrome (abst) receptors, IgA nephropathy Tamm-Horsfall protein excretion, pregnancy (abst) Taurine efflux, extracellular osmolality (abst) reabsorption, furosemide (abst)

690 177 1004

678 997

99mTcDMSA renal uptake rate, UUO, children (abst).... 344 Thalidomide, refractory systemic vasculitis (abst) Theophyllin, HCO1 loss, UTI, DM, post-transplant

672

1001 (abst) Thrombocytopenia, heparin, anaphylaxis, post1003 parathyroidectomy (abst) Thrombosis 990 coagulation regulatory protein, CAPD (abst) 1483 renal vein, adult NS, fibrinolysis (abst) 1364 vascular intra-access pressure 1482 Thrombotic microangiopathy, post-transplant (abst) Thromboxane B2 PGF1 cyclosporin, post-transplant 360 (abst) Thromboxane (TxA2) 676 endotoxin, glomerular resistance (abst) 686 IL-I regulation, MC (abst) 1168 long-term inhibition, lupus nephritis 369 Tidal peritoneal dialysis prescription, PET (abst) Tissue expression factor, interstitial renal fibrosis (abst) . . 1005 388 Tissue specific cell lines

1898

Toirestat, afferent arteriolar pressure (abst) Torasemide, dosages, CRF (abst)

Subject Index: Vol. 47

1221 992

Toxicity 1677 heavy metal, rBAT, amino acids 395 mercury, kidney cells 1007 opiates, extracorporeal detoxification (abst) 988 propafenone, hemoperfusion (abst) 1274 Transcytosis, endocytosis of albumin gold 1002 Transdifferentiation, renal fibrogenesis (abst) 1068 Transferrin gene expression Transforming growth factor-n (TGF-/3) an overview 49:S-19 692 ANP, growth suppression, MC (abst) 363 cell specific regulation, ECM (abst) 361 chronic allograft rejection (abst) 1006 CsA, cell proliferation (abst) 678 decorin mRNA, DN (abst) 691 GS, PAN, MCP-1 (abst) LTBP, renal localization 733 mediates GS 49:S-59 351 mRNA detection, diabetes (abst) 665 neutral endopeptidase, EGF, VSMC (abst) 673 production, MC, glomeruli, high glucose (abst) 1003 proteinase, LLC-PK1 cells, protein kinase (abst) 692 wound healing (abst) Transplantation. See also Allografts; Rejection ABO-incompatible, autoimmune hemolytic anemia 362 (abst) 362 acute pyelonephritis, graft kidney, RF (abst) 370 adhesion molecules distribution, biopsy (abst) 368 ADPKD patients (abst) 706 allogeneic, long-term tolerance (abst) 983 aluminum toxicity (abst) 984 analgesic nephropathy, urothelial carcinoma (abst) anti-HCV positive donors 236 708 anti-IL-2R MoAb prevents rejection (abst) 964 AP measurement, acutely dilated pyelon (abst) AV regurgitation, hypertension, nephrosclerosis (abst) . . 981 971 C4d deposits, "early graft dysfunction" (abst) cardiovascular events after (abst) 979 chronic loss 1491 368 coronary risk, elderly (abst) 966 CsA, plasma prorenin, bone marrow (abst) 970 de novo diabetic GS, post-transplant (abst) 361 enalapril, erythrocytosis (abst) 984 femoral head osteonecrosis, post-transplant (abst) 963 graft related HLA-antibodies (abst) HCV and HBV after (abst) 1001 HLA-I antigen serum levels (abst) 359 708 HLA-identical, Na homeostasis, dopamine (abst) 965 hyperparathyroidism, allograft (abst) 370 hyperparathyroidism (abst) 998 hypertension, post-transplant (abst) 974 impairment RFR, recipients (abst) 357 lipid profiles, Lp(a) (abst) 1005 lipoprotein, serum (abst) 360 living donor (abst) 1004 LVH in recipients (abst) 980 lymphoma, EBV, post-transplant (abst) 988 lymphoma, post-transplant (abst) 980 malignancy, associated factors (abst) 1006 malignant tumors after (abst) metabolic risk factors (abst) 979, 980 977 metabolism, FK506, post-transplant (abst) microscopic polyarteritis, anti-MPO antibodies (abst) . . . 368

1005 non-immunologic factors (abst) 707 number of nephrons, pre-transpiant (abst) pancreas/kidney, UT!, DM, NaHCO3 loss, theophyllin 1001 (abst) 975 predisposition, post-transplant DM (abst) 975 predisposition to erythrocytosis (abst) 369 pregnancy after (abst) 1006 reactivated EBV, sero-diagnosis (abst) 362 rhabdomyolysis, lipid-lowering agents (abst) 981 survival, diabetic/non-diabetic patients (abst) 1482 thrombotic microangiopathy (abst) 994 urinary proteins, 2-year graft function (abst) urinary proteins, biochemistry characterized (abst) . . . . 1001 360 urinary TxB2, PGF1 cyclosporin (abst) 1005 UT! bacterial spectrum (abst) vessel wall properties, BP (abst) 964 566 Triglycerides in nephrotic syndrome Tuberculosis in HD unit (abst) 359 Tubular cells distinctive adherence, E. coli (abst) 688 299 growth and exogenous glutamine 1336 heme-induced cytoresistance 968 1,25-D3 increases !CAM-1, EC (abst) transport, extracellular nucleotides 1500 1647 transport, renal organic cation 818 Tubular hypertrophy, IGF-1, IGF binding protein-i Tubular hypomagnesemia-hypokalemia with 547 hypocalciuria 717 Tubular morphogenesis/differentiation Tubular regeneration, hypoxia, ET-i, autocrine growth 693 loop (abst) Tubular salt load, DNA synthesis 1615 Tubulogenesis, impaired, of ADPKD cells 861 Tubuloglomerular feedback 702 glomerular pressure, analbuminemic rats (abst) intratubular injections, NO blockade (abst) 695 1252 NLA reabsorption 1285 Tubulointerstitial fibrosis, Ang II, UUO 988 Tubulointerstitial injury, urine electrophoresis Tumefactive megalocytic interstitial nephritis, E. coli 986 (abst) Tumor necrosis factor-a (TNF-a) 122 biphasic increase, MRL-lpr mice 1537 mRNA, commercial dialysate, NF-kB activity production, chronic HD 559 704 PTEC production, IL-8 (abst) 705 PTEC production, MCP-1 (abst) Tumor necrosis factor (TNF) 677 endothelial cells, ligand receptors (abst) 705 endothelial cells, verocytotoxin receptor (abst) 1005 12(R)-HETE, ion transport, colon (abst) 1222 21 -aminosteroids, ischemia/reperfusion injury (abst) 964 2-methylcitric acid, uremia (abst) Tyrosine kinases 774 EGF receptor, kidneys 660 endothelial cells, PDGF, angiogenesis (abst) 1354 phosphorylation, COX I! regulation, IL-i/I 687 phosphorylation, PDGF, mesangial cells (abst)

U Ultra-fast computer tomography, coronary arteries (abst). . 967 Ultrafiltrate conductivity kinetic model (abst) 367 Ultrafiltration 1242 charge selectivity dextran sulfate uptake, glomerular cells 945

Subject Index: Vol. 47

Ultraviolet irradiation, HD water disinfection (abst) Unilateral ureteral obstruction (UUO) Ang II, tubulointerstitial fibrosis pycloplasty, children (abst) Uninephrectomy analbuminemia, hyperlipidemia, GS plasma/urine ET-1 (abst) Urea kinetic modeling (Kt/V) I32-M deposits, HD

nutritional assessment, CAPD (abst) one-compartment (blood), HD (abst) predicting dialysis delivery ultrafiltrate conductivity, PFD (abst) Urea reduction ratio, dialysis delivery Uremia 1,25(OH)2D3 receptor level (abst) arterial/venous changes, independent of BP (abst) f32-M deposits, math model calcitriol i.v., insulin sensitivity carbamylated hemoglobin as index (abst) erythrocytes, S-adenosylhomocysteine GFR elevation, glucagon, cAMP (abst)

1481 1285 344

442 1008 1453 358 970 319 367 319

665 963 1453 200 1219 247 685

granulocyte inhibitory protein (GIP) and DIP (abst).... 672

HBV vaccine non-responders, rIL-2 (abst) 1483 1522 hepatocyte metabolism 348 idiopathic nephrotic syndrome (abst) immunoglobulin light chains, PMN functions (abst) .... 969 1732 LDL metabolism, dialysis 964 metabolites, serum concentrations (abst) 510 p-cresol, phagocyte function 1797 PTH receptor down-regulation secondary hyperparathyroidism, bone disease, DM . . . . 1746 Ureteric bud cell expression K channel (abst) 661 978 ontogeny, epithelial polarity (abst) 971 Urinalysis, heavy metal exposure (abst) Urinary excretion 346 2-M, children, NS, proteinuria (abst) 1218 f32-M, idiopathic membranous nephropathy (abst) 369 enzymes, contrast media, nitrendipine (abst) 968 enzymes, infradian bioperiodicity, age (abst) enzymes, renal tubular brush border (abst) 989 Urinary flow rate 685 dependence of pressure diuresis (abst) renal reserve measurement (abst) 666 855 Urinary neutral endopeptidase, salt loading 624 Urinary parameters, pH in acidosis Urinary proteins biochemical characterization, post-transplant (abst). . . . 1001 concentration/intake, in health and CRF 7 369 excretion, contrast media, nitrendipine (abst) 1004 excretion, pregnancy (abst) 994 predict 2-year graft function (abst) 1811 Urinary tract disease, ancient Babylonia Urinary tract infection (UTI) 1005 bacterial spectrum, post-transplant (abst) post-pancreas/kidney transplant, DM, NaHCO3 loss, 1001 theophyllin (abst) Urine CD, papillary pH gradient, diuresis, vasa recta 681, 987 (abst) 664 concentration, organic osmolytes, diuresis (abst) 988 Urine electrophoresis, interstitial nephritis (abst) Urodilatin 1009 ET-1, renal microcirculation (abst)

isolated perfused kidney/neonatal kidney cells (abst). renal effects Urokinase, RA pressure, norepinephrine (abst) Urothelial carcinoma (abst) UTP, extracellular, membrane voltage, MC (abst)

1899 982 1558 352 984 700

V

Vasa recta diuresis, papillary pH gradient, CD urine (abst) . . . 681, 987 Vascular access 1484 clotting, SLE, anticardiolipin antibodies (abst) clotting AV fistulae, coagulation abnormalities (abst) . . 1484 intra-access pressure, thrombosis 1364 peripheral vein/low blood flow methods (abst) 356 seroma formation, PTFE grafts as AV fistulae (abst) .. 1484 Vascular changes 963 arterial/venous, independent of BP, uremia (abst) 169 compliance, salt sensitivity 360 reactivity, CsA (abst) renal resistance arteries, insulin (abst) 997 Vascular endothelial growth factor (VEGF) 660 human kidney receptors (abst) 983 renal hemodynamics (abst) 703 Vascular rejection, biopsy (abst) Vascular smooth muscle cells (VSMC) 1057 high glucose, PKC isoforms 78 Na/H antiporter (NHE-1 isoform), SHR

PDGF, PKC-a/ (abst) TGF-p, EGF, neutral endopeptidase (abst)

Vasculitis ANCA-positive, pulmonary hemorrhage (abst) leukocytes, ICAM-1, VCAM-1, IL-la (abst) leukocytes, ICAM-1, VCAM-l (abst) MHC class II alleles pathogenesis, neutrophils (abst) refractory systemic, thalidomide (abst) Vasoactive substances

670 665 365 672 363 294 672 672

interact with urodilatin 1558 plasma factor, MCD, glomerular permeability (abst). . . 1218 U-937 monocyte MC adhesion (abst) 660 Vasoconstriction endotoxin, preglomerular juxtamedullary vessels (abst). 1216 renal resistance arteries, insulin (abst) 997 Vasopressin 696 AQP-CD water channel (abst) 682 arginine, natriuresis (abst) 706 DDAVP, vasodilation, EH (abst) 683 hyaluronate hydrolases, urinary bladder (abst) 683 lithium reabsorption (abst) 687 polyunsaturated free FA, antidiuresis (abst) 679 renal development (abst) 660 renal response (abst) WCH-CD endosome distribution, CD cells (abst) 675 Vasopressin V2 receptors 668 cortico-papillary NaC1 gradient (abst) 344, 991 mutation, X-linked nephrogenic DI (abst) VCAM-1 1383 allograft rejection, JCAM-1 370 counter-receptors, crescentic GN (abst) 350 hemorrhagic fever with renal syndrome (abst) 363 leukocytes, renal vasculitis, ICAM-l (abst) 672 leukocytes, renal vasculitis, IL-la (abst) 989 Wegener's granulomatosis, SLE (abst) Verapamil 344 Ca, mitochondria, respiratory dysfunction (abst)

1900

[Ca2], carbohydrate metabolism, PMNL DNA synthesis, adult MC proliferation (abst) Verocytotoxin producing E. col4 HUS (abst) receptor, endothelial cells (abst) Vessel wall properties ESRD, hyperhydration (abst) post-transplant, hypertension (abst)

Subject Index: Vol. 47

1741 991 1222 705

964 964

973 989 1000 708 1222 661 692

x

w Water channels

AQP-CD water channel, vasopression (abst) CHIP-FA amphibian (abst) WCH-CD endosome distribution, CD cells (abst) Wegener's granulomatosis ANCA inhibits proteinase 3

antiendothelial antibodies (abst) circulating adhesion molecules (abst) with microform of PAN (abst) rabbit ATG therapy (abst) renal histology (abst) Wilm's tumor, proteins, PAX-2 (abst) Wound healing, TGF-13 null mouse (abst)

696 662 675 1528

X-linked nephrogenic diabetes insipidus (abst) .. 344, 364, 991

z Zaprinast, ARF recovery

Zinc protoporphyrin, endogenous iron, HD (abst)

1569 964